

ALLEGATO B (AI FINI DELLA PUBBLICAZIONE)

**Procedura selettiva di chiamata per n. 1 posto di Ricercatore a Tempo
Determinato in tenure track (RTT) Riservata ex Art. 24, Comma 1-bis, L.
240/2010 Dip. Materno Infantile e Scienze Urologiche Cod. Concorso
2024RTTE009 (SPC: 2024-2189-1461-221422)**

**CURRICULUM VITAE
FRANCESCO DEL GIUDICE**

Luogo e data: Roma, 23/08/2024

Francesco Del Giudice

- EDUCATION, TRAINING AND APPOINTMENTS
- ACADEMIC TEACHING ACTIVITIES
- SCIENTIFIC INDICATORS (SCOPUS)
- AWARDS, HONORS and GRANTS
- COMPETITIVE CALL FOR ACADEMIC NATIONAL AND INTERNATIONAL PROJECTS OR GRANTS
- CLINICAL TRIAL INVOLVEMENT
- INTERNATIONAL DIRECTION AND/OR PARTICIPATION IN RESEARCH GROUP ACTIVITIES
- SOCIETY MEMBERSHIPS
- CLINICAL ACTIVITY IN UROLOGY
- NATIONAL and INTERNATIONAL CONFERENCES, ABSTRACTS, & PRESENTATIONS
- ACADEMIC EDITOR AND PEER-REVIEWER FOR INDEXED INTERNATIONAL JOURNALS
- MANUALS and BOOK CHAPTERS IN ACADEMIC TEXTBOOK
- SPOKEN LANGUAGES
- STATISTICAL, COMPUTER AND SOFTWARE SKILLS
- LIST OF INTERNATIONAL PUBLICATIONS OVER THE LAST 10 YEARS (MAX n=12)
- LIST OF INTERNATIONAL INDEXED PUBLICATIONS “In Extenso” (SCOPUS)

Jul 2009:

High School Graduation Liceo Classico Statale "Tito Lucrezio Caro" of Rome.

Exam Score: 96/100.

Sep 2012 – Jun 2015:

Elective Urology Internship,

Department of Gynecological-Obstetric and Urologic Sciences (Clinica "U. Bracci"),
"Sapienza" University of Rome, Policlinico Umberto I Hospital.

Director: Prof. Dr. Vincenzo Gentile.

Oct 2013 – Jun 2015:

Scientific collaboration with the "Liquid Biopsy Unit", Department of Molecular Medicine,
"Sapienza" University of Rome, Policlinico Umberto I Hospital.

Tutor: Prof. Dr. Paola Gazzaniga.

Jun 2013 – Aug 2013:

Visiting Medical Student,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Chair: Prof. Dr. Eila C. Skinner.

Apr 2014 – May 2014:

Visiting Medical Student, Department of Urology,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Chair: Prof. Dr. Eila C. Skinner.

Jul 2014 – Aug 2014:

Clinical Observership, Department of Urology,

Icahn School of Medicine at Mount Sinai Hospital, NY, 10029, USA.

Chair: Prof. Dr. Ashutosh Tewari.

01 Mar 2015 – 30 May 2015:

Research Fellowship in "*Laparoscopic and Robotic Urologic Surgery*"

Department of Urology, University of Heidelberg,

Urologische Klinik - Universitätsklinikum, Heidelberg, Germany.

Tutor and Chair: Prof. Dr. Markus Hohenfellner.

23 Jul 2015:

Degree in Medicine and Surgery,

"Sapienza" University of Rome, Faculty of Farmacy and Medicine,

Policlinico Umberto I Hospital, Rome, Italy.

Degree thesis title: "*Prognostic value of Circulating Tumor Cells (CTCs) in high-risk non-muscle invasive bladder cancer (NMIBC)*".

Final Score: 110 out of 110 *cum Laude*.

01 Sep 2015 – 31 Aug 2016:

Contractualized International Research Consultant,
Department of Urology, Robotic and Minimally Invasive Urologic Surgery Unit,
Stanford University School of Medicine, CA, 94304, USA.

Tutor: Prof. Dr. Benjamin I. Chung

Contract Prot. No. 02/2015

17 Mar 2016:

Italian National Board of the Doctors and Surgeons,
(Esame di Stato per Abilitazione alla Professione Medico-Chirurgo).
Exam Score: 270/270.

11 Aug 2016:

Urology Residency Match
(Scuole di Specializzazione in Medicina SSM- 2016)
Total Score of 110.6/130
National Ranking: 29th out of n=998 participants.

03 Nov 2016 – 03 Nov 2021:

Residency in Urology,
Department of Maternal Infant and Urologic Sciences,
“Sapienza” University of Rome, Faculty of Medicine and Dentistry,
Policlinico Umberto I Hospital, Rome, Italy.

Thesis title: *“Impact of VI-RADS (Vesical Imaging-Reporting and Data System) for Clinical Management of Locally-Advanced Muscle-Invasive Bladder Neoplasms (MIBCs) Candidates for Neoadjuvant Chemotherapy Followed by Radical Cystectomy: Development of the Bladder-MRI Pathway”*.

Tutor: Prof. Dr. Ettore De Berardinis

Final Score: 70/70 *cum Laude*.

01 Nov 2021 – On-going:

PhD student,
Innovative Biomedical Technologies in Clinical Medicine [DOTT] (37° cycle),
Department of Translational and Precision Medicine,
“Sapienza” University of Rome, Faculty of Medicine and Dentistry,
Policlinico Umberto I Hospital, Rome, Italy.

PhD project title: *“Unmasking Residual Disease in Muscle Invasive Bladder Cancer Patients undergoing Neoadjuvant Chemotherapy followed by Radical Cystectomy by utDNA and nacVI-RADS: Predicting Response to Systemic Therapy and Exploring Perspectives for Alternative Therapeutic Pathways”*.

PhD Program Chair: Prof. Dr. Marcello Arca

PhD Tutor: Prof. Dr. Alessandro Sciarra

01 Nov 2019 – 31 Oct 2020:

Post-doctoral Research Fellowship in “Male Sexual Health and Male Infertility”,
Department of Urology, Stanford University School of Medicine, CA, 94304, USA.
Tutor: Prof. Dr. Michael L. Eisenberg

Jan 2021 – Jan 2022:

SIU-AUA Research Fellowship in “*Urologic Oncology*”,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Research Project: “*The Impact of VI- RADS (Vesical Imaging-Reporting and Data System) on the Clinical Management of Locally Advanced Muscle-invasive Bladder Cancers (MIBCs) Candidate for Neoadjuvant chemotherapy (NAC) Followed by Radical Cystectomy (RC): Introductory Steps for the Development of the Bladder-MRI Pathway*”.

Tutor: Prof. Dr. Benjamin I. Chung

Jun 2022 – 06 Jun 2032

ABILITAZIONE SCIENTIFICA NAZIONALE (ASN) - 2021/2023

to the functions of University ASSOCIATE Professor Sector 06/E2 - PLASTIC-
RICOSTRUCTIVE SURGERY, PEDIATRIC SURGERY AND UROLOGY

05 Nov 2021 – 28 Feb 2023:

Contractualized International Research Consultant

Urologic Cancer Epidemiology Laboratory,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Laboratory Director and Tutor: Prof. Dr. Benjamin I. Chung

Contract No. 62811050

01 Feb 2023 – 31 Dec 2023:

Contractualized International Research Consultant

Urologic Cancer Epidemiology Laboratory,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Laboratory Director and Tutor: Prof. Dr. Benjamin I. Chung

Contract No. 63056153

06 Feb 2023 – On-going (Contract End Date: 31 Dec 2024):

Contractualized International Research Consultant

Urologic Cancer Epidemiology Laboratory,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Laboratory Director and Tutor: Prof. Dr. Benjamin I. Chung

Contract No. 63354221

27 Jun 2024 – On-going:

Contractualized Research Collaborator (Assegnista di Ricerca)

Principal Investigator (PI) for the Grant BE-FOR-ERC 2023, SAPIExcellence,

“Sapienza” University of Rome (D.R. n. 979/2023, Prot. N. 0036532).

Project Title: “*Vesical Imaging-Reporting and Data System followed by Photodynamic Trans-urethral Resection of Bladder Tumours to avoid secondary resections in Non-Muscle Invasive Bladder Cancers: the CUT-less Trial*”.

Project Acronym: CUT-less.

Award:

1. **Feb 2017 – Aug 2018**

Responsible Lecturer

Course: “*Urology*”

Accademia Italiana Medici Specializzandi (AIMS), S.R.L.,

Via Ettore Carafa, 57, 70124 Bari (BA), Italy

2. **Feb 2017 – Aug 2018**

Associated Lecturer

Course: “General Surgery”

Accademia Italiana Medici Specializzandi (AIMS), S.R.L.,

Via Ettore Carafa, 57, 70124 Bari (BA), Italy

3. **Jan 2022 – On-going:**

Integrative Didactic Activity (Attività Didattica Integrativa),

Innovative Biomedical Technologies in Clinical Medicine [DOTT] (37° cycle),

Course: “Integrated Pathology II, Diseases of the Uropoietic System – Urology MED/24”,

“Sapienza” University of Rome, Faculty of Medicine, and Dentistry – Course D.

Responsible: Prof. Ettore De Berardinis, Prof. Rosario Cianci

4. **Jan 2022 – On-going:**

Integrative Didactic Activity (Attività Didattica Integrativa),

Innovative Biomedical Technologies in Clinical Medicine [DOTT] (37° cycle),

Course: “Integrated Pathology II, Diseases of the Uropoietic System – Urology MED/24”,

“Sapienza” University of Rome, Faculty of Pharmacy and Medicine – Course B.

Responsible: Prof. Alessandro Sciarra

5. **Oct 2023 – On-going:**

Lecturer in Academic Research (Cultore della Materia),

Course: “Integrated Pathology II, Diseases of the Uropoietic System – Urology MED/24”,

“Sapienza” University of Rome, Faculty of Medicine, and Dentistry – Course D.

Responsible: Prof. Ettore De Berardinis, Prof. Rosario Cianci

6. **Dec 2021 – On-going:**

Lecturer in Academic Research,

Course: “Big Data Analysis in Urologic Oncology: Definitions, Planning and Computation”,

Urologic Cancer Epidemiology Laboratory,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Laboratory Director: Prof. Dr. Benjamin I. Chung

Urology Residency Program Director: Prof. Dr. Simon Conti

7. **Dec 2021 – On-going:**

Lecturer in Academic Research,

Course: “Male Reproductive Medicine and Surgery”,

Department of Urology, Stanford University School of Medicine, CA, 94304, USA.

Laboratory Director: Prof. Dr. Micheal L. Eisenberg

Urology Residency Program Director: Prof. Dr. Simon Conti

8. **Jun 2022 – 06 Jun 2032**

ABILITAZIONE SCIENTIFICA NAZIONALE (ASN) - 2021/2023

to the functions of University ASSOCIATE Professor in the Sector 06/E2 - PLASTIC-
RICOSTRUCTIVE SURGERY, PEDIATRIC SURGERY AND UROLOGY.

9. **Jan 2023 – On-going:**
Lecturer in Academic Research,
Course: "Population-based Insurance Claim Datasets in Urologic Oncology".
Department of Minimally Invasive and Robotic Urology,
University Center of Excellence in Urology, Wrocław Medical University
Responsible: Prof. Dr. Wojciech Krajewski, MD, PhD
10. **Sep 2023 – On-going:**
International Urology Tutor for PhD Courses,
Department of Minimally Invasive and Robotic Urology,
University Center of Excellence in Urology, Wrocław Medical University
Responsible: Prof. Dr. Wojciech Krajewski, MD, PhD
11. **Jul 03 – 05, 2019:**
Scientific Coordinator
Course: "SEMI-LIVE Session 2019"
Challenges in Laparoscopy and Robotics (CILR)
Barcelona – Crowne Plaza Barcelona, Fira Center, Spain
12. **Jun 03 – 05, 2021:**
Scientific Coordinator
Course: "SEMI-LIVE Session 2021"
Challenges in Laparoscopy and Robotics (CILR) 2021
Turin – Virtual Edition
13. **Jun 15 – 17, 2022:**
Scientific Coordinator
Course: "SEMI-LIVE Session 2022"
Challenges in Laparoscopy and Robotics (CILR) 2022
Milan – Grand Hotel Dino, Baveno, Italy
14. **Jun 07 – 09, 2023:**
Scientific Coordinator
Course: "*SEMI-LIVE Session 2023*"
Challenges in Laparoscopy and Robotics (CILR) 2023
Stockholm - Aula Medica, Nobels Väg 6 Solna, Sweden
15. **Jun 07 – 09, 2024:**
Scientific Coordinator
Course: "*SEMI-LIVE Session 2024*"
Challenges in Laparoscopy and Robotics (CILR) 2024
Rome - Auditorium della Tecnica, Rome, Italy
16. **Jun 04 – 06, 2025:**
Scientific Coordinator
Course: "*SEMI-LIVE Session 2025*"
Challenges in Laparoscopy and Robotics (CILR) 2025
Florence
17. **Jun 14 – 15, 2024:**
INVITED FACULTY, Cadaver Laboratory 2024
Course: "*Anatomy Course and Technique for Urologic Surgery*"
ICLO, Via Evangelista Torricelli 15/A – Verona, Italy

SCIENTIFIC INDICATORS (SCOPUS)

- Scientific production (Source **SCOPUS**) available from:
<https://www.scopus.com/authid/detail.uri?authorId=56637122900>
- Scientific production (Source **PubMed**) available from:
<https://pubmed.ncbi.nlm.nih.gov/?term=Del+Giudice+Francesco&sort=date>

Source: **SCOPUS** (from 2014 to 2024):

- TOTAL SCIENTIFIC INDEXED PUBLICATIONS: **227**
- TOTAL CITATIONS: **3686**
- H-INDEX: **35**
- H-INDEX OVER THE LAST 10 YEARS: **35**
- AVERAGE NUMBER OF CITATIONS PER PUBLICATION: **16.1**
- TOTAL "IMPACT FACTOR": **917.7**
- AVERAGE "IMPACT FACTOR" PER PUBLICATION: **4.3**
(Calculated in relation to the year of publication)

1. Mar 16 – 20, 2018

"BEST POSTER" AWARD - 33rd International Congress,
European Association of Urology (EAU) - Copenhagen 2018,
Session: "Accurate staging and stratification of urothelial carcinomas of the bladder and upper tract", Presentation #1136: *"The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)"*.

2. May 03 – 06, 2018

"BEST POSTER" AWARD – 114th International Congress,
American Urological Association (AUA) - Chicago 2019
Session: "Bladder Cancer: Basic Research & Pathophysiology III",
Presentation MP63: *"Circulating Tumor Cells are strong predictor of cancer specific survival in high-risk non-muscle invasive bladder cancer: final analysis of a prospective observational study"*.

3. "Sapienza" University of Rome Financial Year 2018

PRINCIPAL INVESTIGATOR WINNER

Bandi di Avvio alla Ricerca Tipo I, "Sapienza" University of Rome.

Research Project title: *"Co-expression of Programmed Death Ligand 1 (PD-L1) and markers of Epithelial- Mesenchymal Transition (EMT) on Circulating Tumor Cells (CTCs): a possible immune escape mechanism in urothelial carcinomas of the urinary bladder"*.

Protocol Number: AR1181643652BF64,

Funding Awarded:

4. Nov 28, 2019

European Certification E-BLUS

"EUROPEAN TRAINING IN BASIC LAPAROSCOPIC UROLOGICAL SKILLS",
held during the 92nd National Congress, Italian Society of Urology (SIU) – Venice.

5. "Sapienza" University of Rome Financial Year 2019

CO-INVESTIGATOR WINNER

Bandi di Ricerca di Ateneo "Medi", "Sapienza" University of Rome.

Research Project title: *"Oncogenic aberrations in tumor samples from transurethral resection of the bladder as predictive biomarkers of Bacillus Calmette-Guérin efficacy in non-muscle invasive bladder cancer patients"*.

Protocol Number: RM11916B40ED2E05,

Funding Awarded:

6. Academic year 2021-22

SIU-AUA RESEARCH SCHOLARSHIP

Research Fellowship Award by the Italian Society of Urology (SIU) & American Urological Association (AUA)

AUA Site: Department of Urology, Stanford University School of Medicine, Stanford

AUA Tutor: Prof. Benjamin I. Chung.

Awarded Research Proposal: *"The Impact of VI- RADS (Vesical Imaging-Reporting and Data System) on the Clinical Management of Locally Advanced Muscle-invasive Bladder Cancers (MIBCs) Candidate*

for Neoadjuvant chemotherapy (NAC) Followed by Radical Cystectomy (RC): Introductory Steps for the Development of the Bladder-MRI Pathway".

7. "Sapienza" University of Rome Financial Year 2021

PRINCIPAL INVESTIGATOR WINNER

Bandi di Avvio alla Ricerca Tipo II, "Sapienza" University of Rome.

Research Project title: *"Magnetic Resonance Imaging-Targeted Biopsy for Primary Detection of Prostate Cancer: Magnetic Resonance Imaging (MRI) In-Bore versus MRI-Trans-rectal ultrasound (TRUS) Fusion Technique"*.

Protocol Number: AR22117A8AA5ED76,

Funding Awarded:

8. Oct 16, 2021

"PREMIO BRACCI 2021" AWARD,

The best Italian Scientific Article published on an International Peer-Reviewed Journal during 2020.

Article title: *"Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non- muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection"* - European Urology 2020 Jan; 77(1):101-109.

Award received during the 94th National Congress, Italian Society of Urology (SIU), Riccione, Oct 16 - 19, 2021.

9. Dec 2021

OUTSTANDING PAPER AWARD 2021

Asian Journal of Andrology for the best Peer-Reviewed Scientific Article published in 2020

Article title: *"A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility"* AJA 22: 360-367.

Impact Factor 2020: 3.285

Funding Awarded:

10. Jun 27, 2022

FEBU - FELLOW OF THE EUROPEAN BOARD OF UROLOGY

Part 1&2 Written + Oral examinations 2021,

"European Board of Urology" (EBU) held in Warsaw (PL)

11. "Sapienza" University of Rome Financial Year 2022

PRINCIPAL INVESTIGATOR WINNER

Bandi di Avvio alla Ricerca Tipo I, "Sapienza" University of Rome.

Research Project title: *" Diagnostic performance of Node Reporting and Data System 1.0 (Node-RADS) for preoperative prediction of pathological nodal (pN) status from Muscle-Invasive Bladder Cancer (MIBC) undergoing Radical Cystectomy (RC) with Pelvic Lymph-node Dissection (PLND)"*.

Protocol Number: AR12218160DB4AC6,

Funding:

12. 01 Nov 2021 – On-going

MATCH in the PhD Program,

Innovative Biomedical Technologies in Clinical Medicine [DOTT] (37° cycle),

Department of Translational and Precision Medicine,
"Sapienza" University of Rome, Faculty of Medicine and Dentistry,
Policlinico Umberto I Hospital, Rome, Italy.

PhD Research Project selected: *"Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Circulating Tumor Cells (CTCs) to Personalize Treatment in Castration-Resistant Metastatic Prostate Cancer"*.

Final Ranking: 1st out of n=15 eligible participants.

PhD Program Chair: Prof. Dr. Marcello Arca

PhD Tutor: Prof. Dr. Alessandro Sciarra

13. May 13 – 16, 2022

"BEST POSTER" AWARD – 117th International Congress,
American Urological Association (AUA) – New Orleans 2022

Session: " Prostate Cancer: Detection & Screening V",

Presentation MP53-10: *"The role of SelectMDx in men undergoing primary prostate biopsy: a prospective multi-institutional study"*.

14. 06 Jun 2022 – 06 Jun 2032

ABILITAZIONE SCIENTIFICA NAZIONALE (ASN) - 2021/2023

to the functions of University Associate Professor in the Sector 06/E2 - PLASTIC-
RICOSTRUCTIVE SURGERY, PEDIATRIC SURGERY AND UROLOGY.

15. "Sapienza" University of Rome Financial Year 2023

PRINCIPAL INVESTIGATOR WINNER

Bandi di Avvio alla Ricerca Tipo I, "Sapienza" University of Rome.

Research Project title: *"Health-related quality of life (HRQoL) Endpoints from the CUT-less Trial: a Non-inferiority, Phase III, Randomized Controlled Trial of Vesical Imaging-Reporting and Data System followed by Photodynamic Trans-urethral Resection of Bladder Tumors in High-Risk Non-Muscle Invasive Bladder Cancers"*.

Protocol Number: AR123188B3DA32E4,

Funding: -

16. "Sapienza" University of Rome Financial Year 2023

CO-INVESTIGATOR WINNER

Bandi di Ricerca di Ateneo "Medi", "Sapienza" University of Rome.

Research Project title: *"Photodynamic Trans-Urethral Resection of Bladder Tumors (PDD-TURBT) to avoid Secondary Resections in Non-Muscle-Invasive Bladder Cancers (NMIBCs): the CUT-less Trial, a Phase IV, Non-Inferiority, Randomized Controlled Trial from "Sapienza" University of Rome"*.

Protocol Number: RM123188F782420A,

Funding: -

17. 02 Feb 2024

WINNER - PROGETTO "ORIENTAMENTO NEXT GENERATION

Università del Lazio – "Sapienza" – CUP: b81i23000430006

Call for the stipulation of up to a maximum of n=162 contracts reserved for “Sapienza” PhD students for Orientation Course and Coordination Activities to be carried out at Educational Institutions in the Lazio Regional territory.

ID Code: doctoral_students_orientation/2023-24

Final Ranking: 126th out of n=279 eligible participants.

18. **23 May 2023**

"PREMIO MINERVA 2023 " AWARD - Macroarea C

The Minerva Award - IV Edition 2023 for the Scientific Research is indented to the best PhD thesis enrolled in the XXXVI and XXXVII cycles and to the best PhD students regularly enrolled in the XXXIV or XXXIII or XXXII cycle of a PhD course within “Sapienza University of Rome”.

Funding:

19. **07 Dec 2023**

WINNER - Research Funding Proposal

Fondazione Samuel & Barbara Sternberg ETS

Research Project title: *“Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of primary Photodynamic Transurethral Resection of Bladder Tumours (PDD-TURBT) versus conventional white-light TURBT plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) candidate for second look and resection”*

Funding:

20. **19 Jan 2024:**

WINNER - BE-FOR-ERC 2023, Panel Life Sciences (LS)

SAPIExcellence, “Sapienza” University of Rome (D.R. n. 979/2023, Prot. N. 0036532).

Project Title: *“Vesical Imaging-Reporting and Data System followed by Photodynamic Transurethral Resection of Bladder Tumours to avoid secondary resections in Non-Muscle Invasive Bladder Cancers: the CUT-less Trial”*.

Project Acronym: CUT-less.

Final Ranking: 1st out of n=7 eligible finalists

Award:

1. **“Sapienza” University of Rome Financial Year 2018**

Bandi di Avvio alla Ricerca Tipo I, “Sapienza” University of Rome

Role: PRINCIPAL INVESTIGATOR

Research Project title: *"Co-expression of Programmed Death Ligand 1 (PD-L1) and markers of Epithelial- Mesenchymal Transition (EMT) on Circulating Tumor Cells (CTCs): a possible immune escape mechanism in urothelial carcinomas of the urinary bladder"*.

Protocol Number: AR1181643652BF64,

Funding Awarded:

2. **“Sapienza” University of Rome Financial Year 2019**

Bandi di Ricerca di Ateneo “Medi”, “Sapienza” University of Rome.

Role: CO-INVESTIGATOR

Research Project title: *"Oncogenic aberrations in tumor samples from transurethral resection of the bladder as predictive biomarkers of Bacillus Calmette-Guérin efficacy in non-muscle invasive bladder cancer patients"*.

Protocol Number: RM11916B40ED2E05,

Funding Awarded:

3. **“Sapienza” University of Rome Financial Year 2021**

Bandi di Avvio alla Ricerca Tipo II, “Sapienza” University of Rome

Role: PRINCIPAL INVESTIGATOR

Research Project title: *"Magnetic Resonance Imaging-Targeted Biopsy for Primary Detection of Prostate Cancer: Magnetic Resonance Imaging (MRI) In-Bore versus MRI-Trans-rectal ultrasound (TRUS) Fusion Technique"*.

Protocol Number: AR22117A8AA5ED76,

Funding Awarded:

4. **“Sapienza” University of Rome Financial Year 2022**

Bandi di Avvio alla Ricerca Tipo II, “Sapienza” University of Rome

Role: PRINCIPAL INVESTIGATOR

Bandi di Avvio alla Ricerca Tipo I, “Sapienza” University of Rome.

Research Project title: *"Diagnostic performance of Node Reporting and Data System 1.0 (Node-RADS) for preoperative prediction of pathological nodal (pN) status from Muscle-Invasive Bladder Cancer (MIBC) undergoing Radical Cystectomy (RC) with Pelvic Lymph-node Dissection (PLND)"*.

Protocol Number: AR12218160DB4AC6,

Funding:

5. **“Sapienza” University of Rome Financial Year 2023**

Bandi di Avvio alla Ricerca Tipo I, “Sapienza” University of Rome.

Role: PRINCIPAL INVESTIGATOR

Research Project title: *"Health-related quality of life (HRQoL) Endpoints from the CUT-less Trial: a Non-inferiority, Phase III, Randomized Controlled Trial of Vesical Imaging-Reporting and Data System followed by Photodynamic Trans-urethral Resection of Bladder Tumors in High-Risk Non-Muscle Invasive Bladder Cancers"*.

Protocol Number: AR123188B3DA32E4,

Funding:

6. **“Sapienza” University of Rome Financial Year 2023**

Bandi di Ricerca di Ateneo “Medi”, “Sapienza” University of Rome.

Role: CO-INVESTIGATOR WINNER

Research Project title: *"Photodynamic Trans-Urethral Resection of Bladder Tumors (PDD-TURBT) to avoid Secondary Resections in Non-Muscle-Invasive Bladder Cancers (NMIBCs): the CUT-less Trial, a Phase IV, Non-Inferiority, Randomized Controlled Trial from "Sapienza" University of Rome".*

Protocol Number: RM123188F782420A,

Funding Awarded:

7. **02 Feb 2024**

BANDI - PROGETTO “ORIENTAMENTO NEXT GENERATION

Università del Lazio – “Sapienza” – CUP: b81i23000430006

Call for the stipulation of up to a maximum of n=162 contracts reserved for “Sapienza” PhD students for Orientation Course and Coordination Activities to be carried out at Educational Institutions in the Lazio Regional territory.

ID Code: doctoral_students_orientation/2023-24

Final Ranking: 126th out of n=279 eligible participants.

Funding Awarded:

8. **07 Dec 2023**

Call for Urologic Oncology Research Funding Proposal

Role: PRINCIPAL INVESTIGATOR

Fondazione Samuel & Barbara Sternberg ETS

Research Project title: *“Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of primary Photodynamic Transurethral Resection of Bladder Tumours (PDD-TURBT) versus conventional white-light TURBT plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) candidate for second look and resection”*

Funding Awarded:

9. **19 Jan 2024:**

Call for Contractualized Research Collaborator (Assegno di Ricerca)

BE-FOR-ERC 2023, SAPIExcellence

Role: PRINCIPAL INVESTIGATOR

“Sapienza” University of Rome (D.R. n. 979/2023, Prot. N. 0036532).

Project Title: *“Vesical Imaging-Reporting and Data System followed by Photodynamic Trans-urethral Resection of Bladder Tumours to avoid secondary resections in Non-Muscle Invasive Bladder Cancers: the CUT-less Trial”.*

Project Acronym: CUT-less.

Final Ranking: 1st out of n=7 eligible finalists

Award:

1. Nov 2018 – Nov 2020

INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Multicenter, Randomized, Observational, Non-profit Clinical Trial

Title: *"Sildenafil orodispersible film patient-centered experience in the treatment of erectile dysfunction: an observational, prospective, multicenter cohort study"*.

Study Code: 18I-SDF01.

2. Jan 2020 – On-going

LEAD INVESTIGATOR

at the Department of Urology, Stanford University School of Medicine, Stanford, CA, USA, International, Prospective, Multicenter, Non-profit Clinical Trial

by the Department of Urology, University of Florence, Florence, Italy

Title: *"i-RECORD Project (International prospective observational REgistry of COnservative or Radical treatment of localized kiDney tumors)"*.

3. Jan 2020 – On-going:

LEAD INVESTIGATOR

at the Department of Urology, Stanford University School of Medicine, Stanford, CA, USA, International, Prospective, Multicenter, Non-profit Clinical Trial in collaboration with:

by the Department of Urology, University of Illinois at Chicago

Title: *"Patient Scar Assessment After Single-port (SP) versus Multi-port (MP) Robotic-assisted radical prostatectomy (RALP), Cystectomy (RARC) and Radical/partial nephrectomy (RN; PNx): A Comprehensive Multi- Institutional Retrospective Matched-pair Cohort Study"*.

4. Oct 2020 – Jan 2024

INVESTIGATOR

Department of Urology, Stanford University School of Medicine, Stanford, CA, USA, Investigational, Non-profit Clinical Trial

Title: *"Non-invasive External Device for Erectile Dysfunction (3D-Erect): A Pilot Study"*.

ClinicalTrials.gov Identifier: NCT04624126

5. Nov 2020 – Aug 2024

LEAD INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, International, Prospective, Multicenter, Non-profit Clinical trial,

by YAU Urothelial Working Group and EAU Research Foundation - Medical University of Vienna

Title: *"Multicentric prospective T1 urinary bladder cancer (ROGUE-1) registry"*.

6. Jan 2021 – Aug 2024

7. LEAD INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, International, prospective, multicenter, non-profit clinical trial conducted

by British Urology Researchers in Surgical Training (BURST)

Title: *"Transurethral REsection and Single instillation intra-vesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT)"* ClinicalTrials.gov Identifier: NCT05154084.

8. May 2021 – On-going

INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, National, Multicenter, Randomized, Observational, Non-profit Clinical Trial

Title: *"Magnetic resonance imaging (MRI) for nodal staging of primary prostate cancer: Evaluation the accuracy of NODE-RADS score 1.0 and comparison with Briganti 2012, Gandaglia 2017 and Briganti 2019 nomograms"*.

Protocol Code: ICH-016

9. Nov 2021 – On-going

PRINCIPAL INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, for the PhD in Innovative biomedical technologies in clinical medicine [DOTT] (37th cycle),

Title: *"Unmasking Residual Disease in Muscle Invasive Bladder Cancer Patients undergoing Neoadjuvant Chemotherapy followed by Radical Cystectomy by utDNA and nacVI-RADS: Predicting Response to Systemic Therapy and Exploring Perspectives for Alternative Therapeutic Pathways"*

10. Nov 2021 – On-going

LEAD INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, International, Prospective, Multicenter, Non-profit Clinical Trial

by YAU Sexual and Reproductive Health Group and EAU Research Foundation

Title: *"ManAgement of pRiapiSm and its impact on outcomes: an international register (MARS study)"*.

ClinicalTrials.gov Identifier: NCT04932902.

11. Nov 2021 – On-going

LEAD INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, International, Prospective, Multicenter, Non-profit Clinical Trial

by the University of Southern California (USC)

Title: *"Intra-Operative Complication Assessment and Reporting With Universal Standards (ICARUS)"*.

ClinicalTrials.gov Identifier: NCT04994392.

12. Mar 2024 – On-going:

PRINCIPAL INVESTIGATOR

at the Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Sponsored, National, Open-label, Non-Inferiority, Randomized Controlled Trial

Title: *"Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of primary Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) versus conventional white-light TURBT plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) candidate for second look and resection"*

ClinicalTrial.gov ID: NCT05962541

EU CT: 2023-507307-64-00

Funding: Photocure, ASA, Hoffsveien 4, 0275, Oslo, Norway; Medac Pharma Srl, Rome, Italy

1. Jul 2014 – On-going

ACTIVE SCIENTIFIC MEMBER of the International Clinical and Experimental Research Laboratory coordinated by Prof. Simon L. Conti, Assistant Professor of Urology, Urology Residency Program Director, Director of the Stanford Kidney Stones Center, Stanford University School of Medicine, Stanford, CA, USA.

During the years of scientific collaboration, the participation in research activities has led to the development of numerous scientific publications in international journals indexed on the topics of functional urology, endourology of lower and upper urinary tract with particular focus on the treatment of urinary stones. In addition, there have been addressed research issues inherent in the path of specialized urological training and 'Surgical Urological Educational Training with particular attention to the development of international research projects between Italy and the United States.

2. Jul 2013 – On-going:

ACTIVE SCIENTIFIC MEMBER of the International Clinical Research Laboratory coordinated by Prof. Benjamin I. Chung, Associate Professor of Urology, Director of Robotic Surgery Stanford University School of Medicine, Stanford, CA, USA. During the years of scientific collaboration, participation in research activities has allowed the development of numerous scientific publications in international indexed journals related to the topics of urological oncology and functional urology with particular attention to the development of epidemiological research projects using "big data" from "insurance-claims databases".

3. Aug 2018 – On-going:

ACTIVE SCIENTIFIC MEMBER of the International Clinical and Experimental Research Laboratory coordinated by Prof. Michael Eisenberg, Full Professor of Urology, Director of the Male Reproductive Medicine and Surgery, Men's Health, Stanford University, School of Medicine, Stanford, CA, USA. During the years of scientific collaboration, participation in research activities has allowed the development of numerous scientific publications in international indexed journals related to the topics of male and couple infertility, medically assisted fertilization techniques and advanced andrological surgery techniques.

4. Aug Jul 2015 – On-going

ACTIVE SCIENTIFIC MEMBER of the Experimental Research Unit "Liquid Biopsy Unit" coordinated by Prof. Paola Gazzaniga, Associate Professor, Department of Molecular Medicine, "Sapienza" University of Rome. During the years of scientific collaboration, the participation in research activities has allowed to develop numerous scientific publications in international indexed journals and several competitive calls for peer review concerning the methodologies of identification and molecular characterization of Circulating Tumor Cells (CTCs), circulating DNA and microRNA (cfDNA, miRNA) in order to develop predictive and prognostic models for the classification of risk groups in non-muscle invasive bladder urothelial and upper excretory tract cancers.

5. Jan 2019 – On-going

SCIENTIFIC COORDINATOR for the "SEMI-LIVE" session of the European Congress of Laparoscopic Surgery and Urologic Robotics "Challenges in Laparoscopy and Robotics (CILR) from 05/01/2019. The coordination activities for the organization of the CILR - SEMI

LIVE consist in the selection, editing and presentation of international video contributions concerning the most innovative techniques of minimally invasive urological surgery Robotic and Laparoscopic that are annually admitted for presentation in the final program of the congress event.

6. Oct 2019 – Nov 2021

ACTIVE SCIENTIFIC MEMBER of the International Clinical and Experimental Research Laboratory coordinated by Prof. Joseph Liao, Professor and Vice Chair for Academic Affairs, Director of Research in the Department of Urology at Stanford University School of Medicine, Stanford, CA, USA. During the years of scientific collaboration, the participation in research activities has allowed the development of several ongoing research projects related to the topics of Oncological Urology with particular attention to urothelial neoplasms of the bladder and upper excretory tract. Specifically, the research activity has focused on the development and clinical application of artificial intelligence algorithms and software for intra-operative navigation with real-time mode during trans-urethral bladder resection for bladder neoplasms.

7. Sep 2020 – Jan 2022

Participation in International Clinical Research and Precision Medicine activities coordinated by Prof. Cora N. Sternberg, M.D., FACP, Clinical Director, Englander Institute for Precision Medicine Professor of Medicine, Division of Hematology and Medical Oncology. During the scientific collaboration, the participation in research activities have allowed an update and in-depth educational and scientific inherent in the issues of Urological Oncology with particular attention to contemporary methodologies of precision medicine in the field of urothelial neoplasms.

8. Jan 2021 – Jan 2022

Participation in the activities of Clinical Urological Research in collaboration with Dr. Simone Albisinni, Urologist, Department of Urology, Erasme Hospital, Université Libre de Bruxelles. During the scientific collaboration, the participation in research activities has allowed to complete several publications on indexed scientific journals and numerous research projects related to the issues of Urological Oncology with particular attention to the diagnosis and treatment of non-muscle and muscle invasive bladder neoplasms.

9. Apr 2023 – On-going:

FULL member of the panel of experts with specific activity of research and scientific collaboration European and International concerning the Urothelial Cancers (Urothelial Cancer Working Group), of the European Association of Urology (EAU), Section "Young Academic Urologists" (YAU).

10. Apr 2022 – On-going:

Participation in Urology Clinical and Research activities in collaboration with Dr. Wojciech Krajewski, MD, PhD, Urologist, Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wrocław Medical University. During the scientific collaboration, the participation in research activities allowed to complete numerous publications in indexed scientific journals and numerous research projects related to the topics of Urological Oncology with particular attention to the diagnosis and treatment of non-muscle invasive bladder neoplasms and neoplasms of the upper excretory tract.

11. Jan 2021 – Jan 2022:

Participation in Urologic Clinical Research activities coordinated by Prof. Riccardo Autorino, Professor of Surgery (Urology), Director, Urologic Oncology, Division of Urology Lead, Uro-oncology Disease Working Group, Massey Cancer Virginia Commonwealth University Health. During the scientific collaboration, participation in research activities has allowed the development of numerous research projects related to the topics of Urologic Oncology with particular attention on minimally invasive robotic urologic surgery approaches.

12. Mar 2021 – On-going:

ACTIVE SCIENTIFIC COLLABORATION in Urologic Clinical and Translational Research with the Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy (Prof. Dr. Ciro Imbimbo, Dr. Felice Crocetto). During the scientific collaboration, the research activities have allowed the development of numerous research projects related to the topics of Urologic Oncology with particular attention on minimally invasive robotic urologic surgery and translational oncology. The overall number of articles from this scientific collaboration is n=10 international indexed publications.

13. Jun 2021 – On-going:

ACTIVE SCIENTIFIC COLLABORATION in Clinical Research with the Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy (Dr. Marco Moschini) within the YAU/EAU Urothelial Working Group. During the scientific collaboration, the research activities have allowed the development of numerous research projects on the topics of Urologic Oncology with particular attention on clinical multicentric retrospective cohort studies on Urothelial solid cancers. The overall number of articles from this scientific collaboration is n=43 international indexed publications.

14. Apr 2021 – On-going:

ACTIVE SCIENTIFIC COLLABORATION in Clinical Research with the Department of Urology, Medical University of Vienna, 1090 Vienna, Austria (Dr. David D'Andea). During the scientific collaboration, the research activities have allowed the development of numerous research projects and related publications on the topics of Urologic Oncology, within the YAU/EAU Urothelial Working Group. The overall number of articles from this scientific collaboration is n=28 international indexed publications.

Additionally, our Institutions are currently collaborating on an International, Prospective, Multicenter, Non-profit Clinical Trial from the EAU Research Foundation entitled "Multicentric prospective T1 urinary bladder cancer (ROGUE-1) registry".

15. Nov 2022 – On-going:

ACTIVE SCIENTIFIC COLLABORATION in Clinical Research with the Department of Urology UROSUD, La Croix du Sud Hospital, Quint-Fonsegrives, France. (Dr. Benjamin Pradere). During the scientific collaboration, the research activities have allowed the development of numerous research projects and related publications on the topics of Urologic Oncology, within the YAU/EAU Urothelial Working Group. The overall number of articles from this scientific collaboration is n=36 indexed publications.

16. Nov 2022 – On-going:

ACTIVE SCIENTIFIC COLLABORATION in Clinical Research with the Unit of Oncologic Minimally- Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy. (Dr. Andrea Mari). During the scientific collaboration, the research activities have allowed the development of numerous research projects and related publications on the topics of Urologic Oncology, within the YAU/EAU Urothelial Working Group. The overall number of articles from this scientific collaboration is n=40 indexed publications. Additionally, our Institutions are currently collaborating on an International, Prospective, Multicenter, Non-profit Clinical Trial entitled: "i-RECORD Project (International prospective observational REgistry of COnservative or Radical treatment of localized kiDney tumors".

1. **Oct 2016 – On-going**
ORDINARY Member,
Italian Society of Urology (SIU)
2. **Oct 2016 – On-going**
ORDINARY Member,
European Association of Urology (EAU)
3. **Oct 2016 – On-going**
ORDINARY Member,
American Association of Urology (AUA)
4. **Apr 2021 – Mar 2023**
ASSOCIATE Member
Urothelial Cancer Working Group,
European Association of Urology (EAU),
Section Young Academic Urologists (YAU)
5. **Jan 2022 – On-going**
ASSOCIATE EDITOR
“UROONCO BLADDER CANCER (BCa) Educational Platform”
European Association of Urology (EAU).
6. **Jun 27, 2022**
FEBU - FELLOW OF THE EUROPEAN BOARD OF UROLOGY
Part 1&2 Written + Oral examinations 2021,
"European Board of Urology" (EBU) held in Warsaw (PL)
7. **Apr 2023 – On-going**
FULL Member
Urothelial Cancer Working Group,
European Association of Urology (EAU),
Section Young Academic Urologists (YAU)

▪ **03 Nov 2016 – 03 Nov 2021:**

Residency in Urology,
Department of Maternal Infant and Urologic Sciences,
“Sapienza” University of Rome, Faculty of Medicine and Dentistry,
Policlinico Umberto I Hospital, Rome, Italy.

Tutor: Prof. Dr. Ettore De Berardinis

- Outpatient and Day Hospital Services:
 - General Urology Outpatient Clinics
 - Urologic Oncology Outpatient Clinics,
 - Andrology and Male Infertility Outpatient Clinics,
 - Functional Urology Outpatient Clinics
 - Urologic Oncology Day Hospital for Intravesical BCG Clinic
 - Urology Cystoscopy Clinic
 - Day Hospital Urologic Oncology and General Urology Surgery
 - Day Hospital Functional and Reconstructive Urology
- Major Urologic Surgery:
 - Minimally Invasive Urologic Oncology Video Laparoscopic Surgery
 - Minimally Invasive Urologic Oncology Robotic-assisted Surgery
 - Minimally Invasive General Urology Video Laparoscopic Surgery
 - Minimally Invasive General Urology Robotic-assisted Surgery
 - Minimally Invasive Reconstructive Video Laparoscopic Surgery
 - Minimally Invasive Reconstructive Robotic-assisted Surgery
 - Open Urologic Oncology Surgery
 - Open Reconstructive Surgery
 - Open General Urology Surgery
- Lower Tract and Upper Tract Endoscopic Surgery:
 - Lower Tract Urologic Oncology Surgery (i.e., TURBT, Mapping, etc.)
 - Lower Tract General Urology Surgery (i.e., TURP, Urethrotomy, etc.)
 - Upper Tract Urologic Oncology Surgery (i.e., UTUC biopsy, fulguration, etc.)
 - Upper Tract General Urology Surgery (i.e., RIRS, Stenting, etc.)

▪ **01 Nov 2021 – On-going:**

Consultant Urologist,
UOC Urologia – SMUC05,
Policlinico Umberto I Hospital, Rome, Italy
UOC Responsible: Prof. Dr. Giorgio Franco
within the PhD Program in Innovative Biomedical Technologies in Clinical Medicine
Department of Translational and Precision Medicine, “Sapienza” University of Rome,
Responsible Tutor: Prof. Dr. Alesandro Sciarra

- Clinical Activities:
 - Leading the NMIBCs BCG Clinic twice/week,
 - Assisting in Urology In-patient Service management,
 - Participating/Organizing GU Multidisciplinary Unit on Uro-Oncology once /week,
 - Co-Leading General Urology Outpatient Clinics twice/week,

○ Surgical Activities:

- Performing Endoscopic In-Office, Day Hospital and/or In-patient Surgeries (e.g., Cystoscopy, Mapping, Fulguration, TURs, TURPs, etc.)
- Performing diagnostic/conservative surgery for Upper Tract diseases (e.g., fulguration, biopsies, stenting etc.)
- Assisting and/or Performing Fusion Prostatic Biopsies Service
- Assisting and/or Performing Open, Laparoscopic and/or Robotic-assisted Surgeries (Urologic Oncology, General Urology, Reconstructive Urology, Functional Urology)

○ Focus on Prevalent Surgical Procedure Type:

Directly involved in $n \cong 100$ Robotic-assisted procedures

- $\cong 70\%$ Robotic-assisted Radical Prostatectomy (RARP)
out of these $\cong 15\%$ with Pelvic Lymphadenectomy (PLND)
- $\cong 15\%$ Robotic-assisted Simple Prostatectomy (RASP)
- $\cong 10\%$ Robotic-assisted Radical Cystectomy (RARC)
- $\cong 5\%$ Robotic-assisted Partial or Radical Nephrectomy (RAPN, RARN)
- $\cong 5\%$ Robotic-assisted Pyeloplasty

Directly involved in $n \cong 180$ Endoscopic procedures, including but not limited to:

- $\cong 50\%$ TURPs
- $\cong 40\%$ TURBTs
- $\cong 10\%$ Upper Tract Endoscopy for UTUCs

Directly involved in $n \cong 120$ Laparoscopic and/or Open procedures, including but not limited to:

- $\cong 70\%$ Video Laparoscopic Radical Prostatectomy
- $\cong 15\%$ Video Laparoscopic or Open Radical Nephrectomy
- $\cong 10\%$ Video Laparoscopic or Open Radical Nephroureterectomy
- $\cong 10\%$ Video Laparoscopic Pyeloplasty

▪ **Feb 2023 – May 2023:**

Clinical Fellowship,

Endoscopic Lower and Upper Tract Urologic Surgery,

Department of Minimally Invasive and Robotic Urology,

University Center of Excellence in Urology, Wrocław Medical University

Responsible: Prof. Dr. Wojciech Krajewski, MD, PhD

○ Surgical Activities:

- Performing tutored Endoscopic In-Office, Day Hospital and/or In-patient Surgeries (e.g., Cystoscopy, Mapping, Fulguration, TURs, TURPs, etc.)
- Performing tutored diagnostic/conservative surgery for Upper Tract diseases (e.g., fulguration, biopsies, stenting etc.)
- Assisting and Performing Nephrostomy tubes placement
- Assisting and Performing Holmium Laser Enucleation of Prostatic Adenoma (HoLEPs)

▪ **Apr 2023:**

Robotic-assisted Da Vinci® Single Port (SP) Theoretical and Practical Course,

1st University of Illinois Chicago (UIC) International Single Port Course,

Classroom: SP basics Lecture and Video Review

Practical Cadaver Lab SP Retroperitoneal Surgery+

Course Director: Prof. Dr. Simone Crivellaro

11. NATIONAL and INTERNATIONAL CONFERENCES, ABSTRACTS, & PRESENTATIONS

1. **May 2015**

AUTHOR - 110th International Congress

American Urological Association (AUA), New Orleans 2015

Abstract Session: "Kidney Cancer: Surgical Therapy",

Abstract Presentation PD29-10: *"Oncologic outcomes after partial nephrectomy without hilar clamping"*

2. **May 2015**

SPEAKER - 31st International Congress

European Association of Urology (EAU), Munich 2016.

Abstract Session: " Preclinical innovation: Latest news in future treatment of Erectile Dysfunction ",

Abstract Presentation #891: *"Erectile dysfunction correlates with hyperhomocysteinemia: International Index of Erectile Function (IIEF) and penile Doppler ultrasound evaluation "*

3. **Oct 2016**

SPEAKER – 89th National Congress

Italian Society of Urology (SIU), Venice 2016

Abstract Session: "Oncology: basic research",

Abstract Presentation #P226: *"EpCAM (epithelial cell adhesion molecule) as the most common target for circulating tumor cells (CTC) identification: comparison between manual and automated system of isolation and future prospective"*

4. **Oct 2016**

SPEAKER – 89th National Congress

Italian Society of Urology (SIU), Venice 2016

Abstract Session: "Andrology: infertility and male and female sexual dysfunction",

Abstract Presentation P61: *"Hyperhomocysteinemia as an early predictor of erectile dysfunction: International Index of Erectile Function (IIEF) and Penile Doppler Ultrasound correlation with plasma levels of homocysteine"*

5. **Mar 2017**

SPEAKER – 32nd International Congress

European Association of Urology (EAU), London 2017

Abstract Session: "Men's sexual health: Focus on treatment of erectile dysfunction and Peyronie's disease".

Abstract Presentation #372: *"Distal corporal anchoring stitch, a technique to address distal corporal crossovers and impending lateral extrusions of a penile prosthesis"*

6. **Mar 2017**

AUTHOR – 32nd International Congress

European Association of Urology (EAU), London 2017

Abstract Session: "Infertility: Clinical".

Abstract Presentation #451: *"Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: A double blind place controlled (DBPC) study"*

7. **May 2017**

SPEAKER – 112th International Congress

American Urological Association (AUA), Boston 2017

Abstract Session: "Sexual Function/Dysfunction: Surgical Therapy II".

Abstract Presentation PD22-04: *"Distal corporal anchoring stitch" a technique to address distal corporal crossovers and impending lateral extrusions of a penile prosthesis"*

8. Oct 2017

AUTHOR – 90th National Congress

Italian Society of Urology (SIU), Naples 2017

Abstract Session: "Andrology - male infertility".

Abstract Presentation P206: *"Effect of antioxidant supplementation on sperm parameters in oligoastheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study"*

9. Oct 2017

SPEAKER – 90th National Congress

Italian Society of Urology (SIU), Naples 2017

Abstract Session: "Andrology: medical and surgical therapy".

Abstract Presentation P292: *"Distal Corporal Anchoring Stitch: a technique to address distal corporal crossovers and impending lateral extrusions of a penile prosthesis"*

10. Oct 2017

SPEAKER – 90th National Congress

Italian Society of Urology (SIU), Naples 2017

Abstract Session: "Non muscle invasive bladder cancer: diagnosis, therapy and prognostic factors".

Abstract Presentation P19: *"The long-term prognostic value of surviving expressing circulating tumor cells (CTCs) in patients with high-risk non muscle invasive bladder cancer (NMIBC)"*

11. Mar 2018

AUTHOR – 33rd International Congress

International Congress European Association of Urology (EAU), Copenhagen 2018

Abstract Session: "Male infertility: Improving outcomes of surgery and sperm retrieval".

Abstract Presentation #150: *"Varicocele and oligoasthenoteratozoospermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality"*

12. Mar 2018

AUTHOR – 33rd International Congress

European Association of Urology (EAU), Copenhagen 2018

Abstract Session: "Male infertility: Surgical aspects and novel noninvasive treatments for male sexual dysfunction".

Abstract Presentation #1212: *"The "Scratch technique", minimally invasive prosthesis implantation and adjuvant vacuum pump therapy as a multimodal approach in the definitive treatment of patients with Peyronie's disease: A preliminary multicenter experience"*

13. Mar 2018

SPEAKER – 33rd International Congress

European Association of Urology (EAU), Copenhagen 2018

Abstract Session: "Accurate staging and stratification of urothelial carcinomas of the bladder and upper tract".

Abstract Presentation #1136: *"The long-term prognostic value of circulating tumor cells expressing survivin in patients with high-risk non-muscle-invasive bladder cancer (NMIBC)"*

14. May 2018

SPEAKER – 113th International Congress

American Urological Association (AUA), San Francisco 2018

Abstract Session: "Bladder Cancer: Basic Research & Pathophysiology II".

Abstract Presentation MP58-05: *"The long-term prognostic value of circulating tumor cells expressing survivin in patients with high-risk non-muscle-invasive bladder cancer (NMIBC)"*

15. Jun 2018

INVITED MODERATOR - 15th International Congress
Challenges in Laparoscopy and Robotics (CILR),
Leipzig, Germany, Kongresshalle

16. Oct 2018

SPEAKER – 91st National Congress

Italian Society of Urology (SIU), Riccione 2018

Abstract Session: "Non-muscle infiltrating bladder cancer: diagnosis, therapy and prognostic factors".

Abstract Presentation P283: *"Circulating tumor cells are a strong predictor of cancer-specific survival in high-risk non-muscle-invasive bladder cancer: final analysis of a prospective observational study"*

17. Oct 2018

AUTHOR – 91st National Congress

Italian Society of Urology (SIU), Riccione 2018

Abstract Session: "Andrology - infertility".

Abstract Presentation P113: *"Body mass index and age correlate with antioxidants supplementation effect on sperm quality: a double blind place controlled trial on patients with varicocele & oligoasthenoteratozoospermia"*

18. Mar 2019

SPEAKER – 34th International Congress

European Association of Urology (EAU), Barcelona 2019

Abstract Session: "Molecular classification of urothelial tumours and implications for clinical practice".

Abstract Presentation #1077: *"Circulating tumor cells are a strong predictor of cancer-specific survival in high-risk non-muscle invasive bladder cancer: Final analysis of a prospective observational study"*

19. Mar 2019

SPEAKER – 34th International Congress

European Association of Urology (EAU), Barcelona 2019

Abstract Session: "Novel insights and perspectives in penile implant surgery".

Abstract Presentation #345: *" Postoperative vacuum therapy after placement of the AMSTM LGX 700® inflatable penile prosthesis: Penile size outcomes and overall satisfaction"*

20. May 2019

SPEAKER – 114th International Congress

American Urological Association (AUA), Chicago 2019

Abstract Session: "Bladder Cancer: Basic Research & Pathophysiology III".

Abstract Presentation MP63-11: *"Circulating tumor cells are a strong predictor of cancer-specific survival in high-risk non-muscle invasive bladder cancer: final analysis of a prospective observational study"*

21. May 2019

SPEAKER – 114th International Congress

American Urological Association (AUA), Chicago 2019

Abstract Session: "Infertility: Therapy II".

Abstract Presentation MP52-09: *"Body mass index and age correlate with antioxidants supplementation effect on sperm quality: a double blind place controlled trial on patients with varicocele & oligoasthenoteratozoospermia"*

22. Jul 2019

INVITED MODERATOR - 16th International Congress
Challenges in Laparoscopy and Robotics (CILR),
Barcelona, Spain, Crowne Plaza Barcelona Fira Center

23. Oct 2019

SPEAKER – 92nd National Congress

Italian Society of Urology (SIU), Venice 2019

Abstract Session: "Surgical Andrology".

Abstract Presentation SC281: *"Closed suction drainage (CSD) versus no drainage of the scrotum in inflatable penile prosthesis (IPP) placement with minimally invasive infrapubic approach: retrospective comparative outcomes at two high-volume implanting centers"*

24. Oct 2019

SPEAKER – 92nd National Congress

Italian Society of Urology (SIU), Venice 2019

Abstract Session: "Multiparametric MRI and novel biomarkers in the diagnosis of prostate cancer".

Abstract Presentation SC314: *"Implementation of the Select-MDx urine test in the pre-biopsy setting for prostate cancer detection: preliminary results from a single-center prospective pilot study"*

25. Jul 2020

SPEAKER – 35th International Congress Virtual

European Association of Urology (EAU), Amsterdam 2020 - Virtual

Virtual Abstract Session: "Targeted treatment and personalized management of advanced bladder cancer".

Virtual Abstract Presentation #531: *"Prospective validation of the Vesical Imaging-Reporting and Data System (VI-RADS) for discrimination of non-muscle-invasive (NMI) versus muscle-invasive bladder cancer (MIBC) in patients who are candidates for primary transurethral resection of bladder tumors (TURBT)"*

26. Jul 2020

SPEAKER – 35th International Congress Virtual

European Association of Urology (EAU), Amsterdam 2020 - Virtual

Virtual Abstract Session: "Novel technology and techniques in understanding NMIBC".

Virtual Abstract Presentation #660: *"Clinical implications of the Vesical Imaging-Reporting and Data System (VI-RADS) on the management of high-risk non-muscle-invasive bladder cancers (HR-NMIBCs) candidates for repeat transurethral resection (Re-TURBT): A single-center prospective analysis"*.

27. Jul 2020

SPEAKER – 35th International Congress Virtual

European Association of Urology (EAU), Amsterdam 2020 - Virtual

Virtual Abstract Session: "Prostate Cancer, localized - Diagnosis, Pathology & Biopsies".

Virtual Abstract Presentation #56: *"Addition of systematic biopsy (SBx) to targeted biopsy (TBx) at magnetic resonance ultrasound fusion of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized, analysis"*.

28. May 2020

SPEAKER – 115th International Congress Virtual
American Urological Association [AUA], Washington 2020 - Virtual
Virtual Abstract Session: “Bladder Cancer: Invasive II”.
Virtual Abstract Presentation MP55-12: *"Prospective validation of the Vesical Imaging-Reporting and Data System (VI-RADS) for discrimination of non-muscle-invasive (NMI) versus muscle-invasive bladder cancer (MIBC) in patients who are candidates for primary transurethral resection of bladder tumors (TURBT)"*

29. Jan 2021

INVITED MODERATOR – 9th International Congress
International Techno-Urology Meeting (TUM), The Advent of Artificial Intelligence,
Turin, Italy, Virtual Edition

30. Jun 2021

INVITED MODERATOR - 17th International Congress
Challenges in Laparoscopy and Robotics (CILR),
Turin, Istituto di Candiolo, Italy

31. Jul 2021

SPEAKER – 36th International Congress Virtual
European Association of Urology (EAU), Milan 2021
Virtual Abstract Session: “Functional outcome of radical prostatectomy and how we can do better”.
Virtual Abstract Presentation P1160: *"A program of guided biofeedback or electrical stimulation of pelvic floor muscles for early recovery of urinary continence after radical prostatectomy: A single-center study and a meta-analysis of the literature"*

32. Jul 2021

AUTHOR – 36th International Congress Virtual
European Association of Urology (EAU), Milan 2021
Virtual Abstract Session: “Ablative BPO surgery - The world of lasers”.
Virtual Abstract Presentation P0065: *"Prostate vascularization and surgical blood loss during laser holmium enucleation of the prostate (HoLEP): Short term pretreatment with dutasteride"*

33. Jul 2021

SPEAKER – 36th International Congress Virtual
European Association of Urology (EAU), Milan 2021
Virtual Abstract Session: “Prostate cancer screening, biopsy indication protocols and markers”.
Virtual Abstract Presentation P101: *"Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy"*

34. Sep 2021

SPEAKER – 116th International Congress Virtual
American Urological Association (AUA), Las Vegas 2021 Virtual
Virtual Abstract Session: “Prostate Cancer: Detection & Screening II”.
Virtual Abstract Presentation MP26-08: *"Targeted biopsy with magnetic resonance imaging for primary prostate cancer detection: MRI In-bore versus MRI-TRUS fusion technique performed by the same operators' team"*

35. Sep 2021

SPEAKER – 116th International Congress Virtual

American Urological Association (AUA), Las Vegas 2021 Virtual

Virtual Abstract Session: “Bladder Cancer: Non-invasive”.

Virtual Abstract Presentation PD09-01: *"Efficacy of three BCG strains (Connaught, Tice and Rivm) with or without secondary resection (Re-tur) for intermediate/high risk non-invasive bladder cancer: results of a retrospective cohort analysis at a single institution"*

36. Sep 2021

SPEAKER – 116th International Congress Virtual

American Urological Association (AUA), Las Vegas 2021 Virtual

Virtual Abstract Session: “Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Kidney & Bladder II”.

Virtual Abstract Presentation MP29-01: *"Predictors of sepsis or acute pyelonephritis due to obstructive urolithiasis: a 15-year united states cohort study"*

37. Oct 2021

SPEAKER – 94th National Congress

Italian Society of Urology (SIU), Riccione 2021

Abstract Session: “Male Infertility”.

Abstract Presentation SC160: *"Interplay between male testosterone levels and the risk for Subsequent invasive respiratory assistance among COVID-19 patients at Hospital admission"*

38. Oct 2021

SPEAKER – 94th National Congress

Italian Society of Urology (SIU), Riccione 2021

Abstract Session: “Male Infertility”.

Abstract Presentation SC159: *"Increased mortality among men diagnosed with impaired fertility: analysis of US claims data"*

39. Oct 2021

SPEAKER – 94th National Congress

Italian Society of Urology (SIU), Riccione 2021

Abstract Session: “Prostate Cancer - Biopsy”.

Abstract Presentation SC227: *"MRI-directed biopsy for the primary diagnosis of prostate cancer: MRI In-bore vs MRI-TRUS fusion targeted technique performed by a single team reader-operator"*

40. Jan 2022

INVITED MODERATOR – 10th International Congress

International Techno-Urology Meeting (TUM)

Turin, Italy

41. May 2022

SPEAKER – 117th International Congress

American Urological Association (AUA), New Orleans 2022

Abstract Presentation #22-4866: *"Accuracy of the Bladder Imaging-Reporting and Data System (VI-RADS): An Updated Comprehensive Multi- institutional, Multi-readers Systematic Review and Meta-analysis from diagnostic evidence into future clinical recommendations"*.

42. May 2022

SPEAKER – 117th International Congress

American Urological Association (AUA), New Orleans 2022

Abstract Presentation #22-5553: *"The fate of the incidental adrenal mass, continued surveillance versus surgical excision"*.

43. May 2022

SPEAKER – 117th International Congress

American Urological Association (AUA), New Orleans 2022

Abstract Presentation #22-5645: *"MRI-directed biopsy for primary detection of prostate cancer: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques"*.

44. May 2022

SPEAKER – 117th International Congress

American Urological Association (AUA), New Orleans 2022

Abstract Presentation #22-5639: *"Modeling the Contribution of Preoperative VI-RADS Score to Predict Final Pathologic Lymph-Nodes Involvement in Patients with MIBC Undergoing Radical Cystectomy"*.

45. May 2022

AUTHOR – 117th International Congress

American Urological Association (AUA), New Orleans 2022

Abstract Presentation MP40-11: *"Renal function variation after nephroureterectomy for upper urinary tract carcinoma: evaluation in a large multicenter cohort (radical nephroureterectomy outcomes (RANEO) research consortium)"*

46. May 2022

AUTHOR – 117th International Congress

American Urological Association (AUA), New Orleans 2022

Abstract Presentation MP53-10: *"The role of selectmdx in men undergoing primary prostate biopsy: a prospective multi-institutional study"*

47. Jun 2022

INVITED MODERATOR - 18th International Congress

Challenges in Laparoscopy and Robotics (CILR),

Milan, Lago Maggiore, Baveno, Italy

48. Jul 2022

SPEAKER – 37th International Congress

European Association of Urology (EAU), Amsterdam 2022

Abstract Session: "Searching the evidence in urology: Systematic reviews and meta-analysis".

Abstract Presentation A0170: *"Safety and feasibility of outpatient surgery in benign prostatic hyperplasia: A systematic review and meta-analysis"*

49. Jul 2022

SPEAKER – 37th International Congress

European Association of Urology (EAU), Amsterdam 2022

Abstract Session: "Advanced bladder cancer: Staging, predictive factors and systemic therapy".

Abstract Presentation A0903: *"Modeling the contribution of preoperative VI- RADS score to predict final pathologic lymph-node involvement in patients with MIBC undergoing radical cystectomy"*.

50. Jul 2022

SPEAKER – 37th International Congress

European Association of Urology (EAU), Amsterdam 2022
Abstract Session: "NMIBC early diagnosis and improvement of endoscopic management".
Abstract Presentation A0163: *"Comparative efficacy of adjuvant intravesical TICE BCG vs. RIVM for high-risk non-muscle invasive bladder cancer: A Multicenter Propensity Score Matched Analysis"*.

51. Jul 2022

SPEAKER – 37th International Congress
European Association of Urology (EAU), Amsterdam 2022
Abstract Session: "Reproductive health - Male infertility andrological effects of COVID-19".
Abstract Presentation A0809: *"The effect of seminal parameters on pregnancy rate from assisted reproductive technologies: Systematic review and meta-analysis"*.

52. Jul 2022

SPEAKER – 37th International Congress
European Association of Urology (EAU), Amsterdam 2022
Abstract Session: "New insights in the management of upper tract urothelial cancer".
Abstract Presentation A0299: *"Contemporary trends in neoadjuvant and intravesical adjuvant systemic chemotherapy for upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy: Analysis of U.S. claims on perioperative outcomes and health care costs"*.

53. Jul 2022

AUTHOR – 37th International Congress
European Association of Urology (EAU), Amsterdam 2022
Abstract Presentation S232-S233: *"Predictors of residual tumor at re-staging transurethral resection for high-risk non-muscle invasive bladder cancer: Insights from a large multi-institutional collaboration"*

54. Jul 2022

AUTHOR – 37th International Congress
European Association of Urology (EAU), Amsterdam 2022
Abstract Presentation S1708: *"The influence of operative time and blood loss on surgical margins and functional outcomes at laparoscopic versus robotic-assisted radical prostatectomy: A prospective multicenter study"*

55. Oct 2022

SPEAKER – 95th National Congress
Italian Society of Urology (SIU), Riccione 2022
Abstract Presentation SC225: *"Contemporary trends of systemic neoadjuvant and adjuvant intravesical chemotherapy in patients with upper tract urothelial carcinomas undergoing minimally invasive or open radical nephroureterectomy: analysis of US claims on perioperative outcomes and health care costs"*

56. Oct 2022

SPEAKER – 95th National Congress
Italian Society of Urology (SIU), Riccione 2022
Abstract Ref #SC26: *"The accuracy of vesical imaging-reporting and data system (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations"*

57. Oct 2022

AUTHOR – 95th National Congress

Italian Society of Urology (SIU), Riccione 2022

Abstract Ref #S107: *"Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: results from a machine learning-based analysis of a large multi-institutional database"*

58. Oct 2022

AUTHOR – 95th National Congress

Italian Society of Urology (SIU), Riccione 2022

Abstract Ref #S114: *"How to predict outcomes from a biofeedback and pelvic floor muscle electric stimulation program in patients with urinary incontinence after radical prostatectomy"*

59. Oct 2022

AUTHOR – 95th National Congress

Italian Society of Urology (SIU), Riccione 2022

Abstract Ref #S31: *"Cryo-and radiofrequency versus microwave ablation for renal mass: multicenter comparative analysis"*

60. Oct 2022

AUTHOR – 95th National Congress

Italian Society of Urology (SIU), Riccione 2022

Abstract Ref #S141: *"Robot-assisted partial nephrectomy versus percutaneous ablation for completely endophytic renal masses: a multicenter analysis with a minimum 3-year follow-up"*

61. Oct 2022

AUTHOR – 95th National Congress

Italian Society of Urology (SIU), Riccione 2022

Abstract Ref #S116: *"Influence of operative time and blood loss on surgical margins and functional outcomes for laparoscopic versus robotic-assisted radical prostatectomy: a prospective analysis"*

62. Oct 2022

AUTHOR – 95th National Congress

Italian Society of Urology (SIU), Riccione 2022

Abstract Ref #S141: *"Robot-assisted partial nephrectomy versus percutaneous thermal ablation for renal mass in solitary kidney: a multicenter analysis"*

63. Feb 2023

INVITED MODERATOR – 10th International Congress

International Techno-Urology Meeting (TUM)

Turin, Italy

64. Mar 2023

SPEAKER – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Session: *"How can we improve staging and outcomes of muscle-invasive bladder cancer patients?"*

Abstract Presentation A1060: *"A novel pathway to detect Muscle-Invasive Bladder Cancer (MIBC) combining clinical features and preoperative VI-RADS scoring criteria: Results from a prospective multicenter validation analysis"*.

65. Mar 2023

SPEAKER – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Session: *"How can we improve staging and outcomes of muscle-invasive bladder cancer patients?"*

Abstract Presentation A1064: *"Diagnostic performance of Node-RADS by preoperative CT scans for prediction of pathological nodal (pN) status from Muscle-Invasive Bladder Cancers (MIBCs) undergoing Radical Cystectomy (RC) with extended Pelvic Lymph-node Dissection (ePLND)".*

66. Mar 2023

SPEAKER – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Presentation: *"Time for double-J (DJ) indwelling ureteral stent removal following primary or salvage pyeloplasty in US adult patients is affected by demographic and perioperative factors: results from a large population-based cohort analysis".*

67. Mar 2023

SPEAKER – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Session: "Non-muscle invasive bladder cancer: From diagnosis to follow-up"

Abstract Presentation A0606: *"5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers for Benign Prostatic Hyperplasia do not lower the risk of incident Bladder Cancer: an analysis of US insurance claims data".*

68. Mar 2023

SPEAKER – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Presentation: *"Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States".*

69. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S608: *"Immune responses against SARS-CoV-2 wildtype in unvaccinated patients with high-risk NMIBC undergoing intravesical BCG therapy".*

70. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S1010-S1011: *"Survival analysis of patients with T1LG bladder cancer treated with BCG immunotherapy".*

71. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S459: *"Is there any difference between cognitive and fusion biopsies when performed by residents?".*

72. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S1034: *" Do serum inflammatory indexes predict prostatic inflammation".*

73. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S1893-S1894: *"The role of extended versus standard lymphadenectomy lymph node dissection in clinically lymph node-positive bladder cancer"*.

74. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S401-S402: *"Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: Results from a machine learning-based analysis of a large multi-institutional database"*.

75. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S1155-S1156: *"Trends and incidence of reported events associated with staplers: An analysis of the food and drug administration's manufacturer and user facility device experience database"*.

76. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S1816: *"Major adverse cardiovascular events (MACE) related to phosphodiesterase 5 inhibitors (PDE5i): Analysis of real-life data from Eudra-Vigilance (EV) database"*.

77. Mar 2023

AUTHOR – 38th International Congress

European Association of Urology (EAU), Milan 2023

Abstract Ref #S1021: *"Clinical validation of the EAU2021 intermediate risk NMIBC definition and implications for adjuvant treatment: A multicenter YAU Urothelial Collaboration"*.

78. Apr 2023

SPEAKER – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Session: "BPH: Surgical Therapy & New Technology".

Abstract Presentation PD41: *"Trends in the diagnostic and surgical management of Benign Prostatic Hyperplasia (BPH) in the United States: annual changes in the selection of treatment options and average costs differential for diagnostic/surgical technique"*.

79. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation MP34-14: *"Medications mostly associated with urinary tract infections (UTIS): assessment of the eudravigilance (EV) and food and drug administration (FDA) pharmacovigilance databases entries"*.

80. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation MP08-03: *"Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: results from a machine learning-based analysis of a large multi-institutional database"*.

81. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation PD34-09: *"The association between organophosphate insecticides and kidney stone formation among US adults"*.

82. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation MP24-13: *"Prostate shape and intravesical prostatic protrusion assessed by magnetic resonance imaging are related to urinary symptoms"*.

83. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation PD11-03: *"The use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events"*.

84. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation PD13-09: *"Clinical validation of the eau2021 intermediate risk nmibc definition and implications for adjuvant treatment: a multicenter YAU urothelial collaboration"*.

85. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation MP35-11: *"Trends and incidence of reported events associated with ureteral stents: an analysis of the food and drug administration's manufacturer and user facility device experience database"*.

86. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation PD26-06: *"The association between insomnia, insomnia medications, and erectile dysfunction"*.

87. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation PD26-01: *"Worldwide temporal trends in penile length: a systematic review and meta-analysis"*.

88. Apr 2023

AUTHOR – 118th International Congress

American Urological Association (AUA), Chicago 2023

Abstract Presentation MP46-19: *"The role of extended versus standard lymphadenectomy lymph node dissection in clinically lymph node-positive bladder cancer"*.

89. Jun 2023

INVITED MODERATOR - 19th International Congress

Challenges in Laparoscopy and Robotics (CILR),

Stockholm - Aula Medica, Nobels Väg 6 Solna, Sweden

90. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica: diagnosi e staging"

Abstract Presentation SC1: *5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-b) for benign prostatic hyperplasia do not lower the risk of incident bladder cancer: united states insurance claims data".*

91. Oct 2023

AUTHOR – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica: diagnosi e staging"

Abstract Presentation SC4: *"Clinical validation of the intermediate-risk non-muscle invasive bladder cancer sub stratification model proposed by the IBCG (international bladder cancer group): a multicenter YAU urothelial collaboration".*

92. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica: diagnosi e staging"

Abstract Presentation SC8: *"A novel pathway to detect Muscle-Invasive Bladder Cancer (MIBC) combining clinical features and preoperative VI-RADS scoring criteria: Results from a prospective multicenter validation analysis".*

93. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica: diagnosi e staging"

Abstract Presentation SC11: *"Diagnostic performance of NODE-rads by preoperative CT scan for prediction of pathological nodal (PN) status from muscle-invasive bladder cancers (MIBCs) undergoing radical cystectomy (RC) with extended pelvic lymph-node dissection (ePLND)".*

94. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Patologia surrenalica"

Abstract Presentation SC43: *"Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of us claims data on contemporary socio-demographic predictors and perioperative outcomes".*

95. Oct 2023

AUTHOR – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Ricerca di base"

Abstract Presentation SC44: *"Altmetrics of urology journals: where do we stand?".*

96. Oct 2023

AUTHOR – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumore della prostata: sorveglianza attiva, terapie focali, ormonali e radioterapia"

Abstract Presentation SC241: *"Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive non-metastatic prostate cancer: comparative analysis in terms of CRPC-M0 progression".*

97. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Trattamento delle stenosi ureterali"

Abstract Presentation SC196: *"Time for double-j (DJ) indwelling ureteral stent removal following primary or salvage pyeloplasty in us adult patients is affected by demographic and perioperative factors: results from a large population- based cohort analysis"*.

98. Oct 2023

AUTHOR – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica non muscolo invasivo: trattamento"

Abstract Presentation SC4: *"Clinical validation of the EAU intermediate risk NMIBC definition and implications for adjuvant treatment: a multicenter YAU urothelial collaboration"*.

99. Oct 2023

AUTHOR – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica non muscolo invasivo: trattamento"

Abstract Presentation SC211: *"Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: results from a machine learning-based analysis of a large multi-institutional database"*.

100. Oct 2023

AUTHOR – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica non muscolo invasivo: trattamento"

Abstract Presentation SC212: *"The impact of variant histologies in patients with pT1 non-muscle invasive bladder cancer undergoing repeated transurethral resection of bladder tumor"*.

101. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica non muscolo invasivo: trattamento"

Abstract Presentation SC214: *"Prognosis of patients with T1 low-grade urothelial bladder cancer treated with BCG"*.

102. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Tumori della vescica non muscolo invasivo: trattamento"

Abstract Presentation SC217: *"Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumor quality indicators"*.

103. Oct 2023

SPEAKER – 96th National Congress

Italian Society of Urology (SIU), Rome 2023

Abstract session: "Andrologia 2"

Abstract Presentation SC309: *"Systematic review and meta-analysis of serum total testosterone (TT) and luteinizing hormone (LH) variations across hospitalized covid-19 patients and healthy controls: a proof of interplay between host immune-response, hypothalamic-pituitary-gonadal axis (HPG) and severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)"*.

104. **Oct 2023**
AUTHOR – 96th National Congress
Italian Society of Urology (SIU), Rome 2023
Abstract session: "Tumore della prostata: staging"
Abstract Presentation SC355: *"Comparison of four validated nomograms (memorial sloan kettering cancer center, briganti 2012, 2017, and 2019) predicting lymph node invasion in patients with high-risk prostate cancer candidates for radical prostatectomy and extended pelvic lymph node dissection"*.
105. **Oct 2023**
SPEAKER – 96th National Congress
Italian Society of Urology (SIU), Rome 2023
Abstract session: "Andrologia 3"
Abstract Presentation SC364: *"The risk of cardiovascular and cerebrovascular disease in men with a history of priapism"*.
106. **Oct 2023**
SPEAKER – 96th National Congress
Italian Society of Urology (SIU), Rome 2023
Abstract session: "Andrologia 3"
Abstract Presentation SC365: *"Association between priapism and HIV disease and treatment"*.
107. **Oct 2023**
SPEAKER – 96th National Congress
Italian Society of Urology (SIU), Rome 2023
Abstract session: "Calcolosi urinaria 1"
Abstract Presentation SC396: *"Characteristics and predictors of sepsis or acute pyelonephritis (APN) in combination with ureteral stone in the United States: a large population-based cohort analysis"*
108. **Oct 2023**
AUTHOR – 96th National Congress
Italian Society of Urology (SIU), Rome 2023
Abstract session: "Tumore di prostata: diagnosi e screening 2"
Abstract Presentation SC448: *"Residents and consultants have equal outcomes when performing transrectal fusion biopsies: a randomized clinical trial"*
109. **Oct 2023**
AUTHOR – 96th National Congress
Italian Society of Urology (SIU), Rome 2023
Abstract session: "Tumore di prostata: diagnosi e screening 2"
Abstract Presentation SC449: *"Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase ix expression and activity and low Ph"*
110. **Apr 2024**
AUTHOR – 39th International Congress
European Association of Urology (EAU), Paris 2024
Abstract Ref #S297-S298: *" Natural history of cN+ bladder cancer treated with radical cystectomy with or without perioperative treatment"*.
111. **Apr 2024**
AUTHOR – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref #S872: *"The optimal way to determine kidney function for cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer: A European Association of Urology young academic urologists urothelial cancer working group multi-institutional study"*.

112. **Apr 2024**

SPEAKER – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref # S315-S316: *"The impact of venous thromboembolism on bladder cancer patients undergoing open or minimally-invasive radical cystectomy in the United States: Perioperative outcomes and health-care costs from insurance claims data"*.

113. **Apr 2024**

AUTHOR – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref #S383-S384: *"Is there a role for Bacillus Calmette-Güerin in very high-risk non-muscle invasive bladder carcinoma? Multicenter analysis of oncological outcomes and risk dynamics"*.

114. **Apr 2024**

AUTHOR – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref #S1357: *"Diagnostic accuracy and inter-reader agreement of nac-VIRADS scoring system: A prospective validation study"*.

115. **Apr 2024**

AUTHOR – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref #S1349-S1350: *"Risk of upper urinary tract dissemination in cT3 bladder cancer patients treated with Double J stent versus nephrostomy tube prior to radical cystectomy"*.

116. **Apr 2024**

AUTHOR – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref #S2237: *"Multicentre study on premature ejaculation treatment with pelvic floor muscle rehabilitation: Analysis of 5 years results"*.

117. **Apr 2024**

AUTHOR – 39th International Congress

European Association of Urology (EAU), Paris 2024

Abstract Ref #S1942: *" The optimal number of induction chemotherapy cycles in cN+ bladder cancer"*.

118. **May 2024**

AUTHOR – 119th International Congress

American Association of Urology (AUA), San Antonio 2024

Abstract Ref PD34-12: *"The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer"*.

119. **May 2024**

AUTHOR – 119th International Congress

American Association of Urology (AUA), San Antonio 2024

Abstract Ref #MP38-20: *"Risk of upper urinary tract dissemination in cT3 bladder cancer patients treated with double-j stent versus nephrostomy tube prior to radical cystectomy"*.

120. **May 2024**

AUTHOR – 119th International Congress

American Association of Urology (AUA), San Antonio 2024

Abstract Ref #MP27-20: *"New minimally invasive techniques versus gold standard approach for middle volume (30-80 ml) prostates: a multicentre prospective randomized study"*.

121. **May 2024**

AUTHOR – 119th International Congress

American Association of Urology (AUA), San Antonio 2024

Abstract Ref # MP45-20: *"The association between prescription medications and kidney stone prevalence among US adults"*.

122. **May 2024**

AUTHOR – 119th International Congress

American Association of Urology (AUA), San Antonio 2024

Abstract Ref #PD52-02: *"Multicentre study on premature ejaculation treatment with pelvic floor muscle rehabilitation: analysis of 5 years results"*.

123. **May 2024**

SPEAKER – 119th International Congress

American Association of Urology (AUA), San Antonio 2024

Abstract Ref #PD02-05: *"The impact of venous thromboembolism on muscle invasive bladder cancer (MIBC) patients undergoing open or minimally-invasive radical cystectomy in the United States: perioperative outcomes and health-care costs from insurance claims data"*.

124. **Jun 2023**

INVITED MODERATOR - 19th International Congress

Challenges in Laparoscopy and Robotics (CILR),

Rome – Auditorium della Tecnica, Italy

125. **Oct 2024**

SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)

Italian Society of Urology (SIU), Bari 2024

Abstract session: "Tumore vescicale non muscolo invasivo 2"

Abstract Presentation SC21: *"Non-inferiority, phase IV, randomized controlled trial of Vesical Imaging-reporting and Data System (VI-RADS) followed by primary Photodynamic trans-urethral resection of bladder tumours (PDD-TURBT) versus conventional white light TURBT plus second-TURBT (Re-TURBT) in non-muscle-invasive bladder cancers (NMIBCs) candidate for Second-look and resection: the CUT-less trial"*.

126. **Oct 2024**

SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)

Italian Society of Urology (SIU), Bari 2024

Abstract session: "Tumore vescicale non muscolo invasivo 2"

Abstract Presentation SC23: *" Photodynamic diagnosis (PDD) directed biopsies vs white light bladder mapping in patients with positive cytology and negative preoperative workup: an international multicenter retrospective study"*.

127. **Oct 2024**
SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)
Italian Society of Urology (SIU), Bari 2024
Abstract session: “Tumore vescicale non muscolo invasivo 1”
Abstract Presentation SC164: *"The impact of venous thromboembolism on non-muscle invasive bladder cancer patients undergoing trans-urethral resection of bladder tumor (TURBT) and/or minor in-office procedures in the United States: perioperative outcomes and health-care costs from insurance claims data"*.
128. **Oct 2024**
SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)
Italian Society of Urology (SIU), Bari 2024
Abstract session: “Tumore vescicale muscolo invasivo 1”
Abstract Presentation SC169: *"The impact of venous thromboembolism on bladder cancer patients undergoing open or minimally-invasive radical cystectomy in the united states: perioperative outcomes and health-care costs from insurance claims data"*.
129. **Oct 2024**
SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)
Italian Society of Urology (SIU), Bari 2024
Abstract session: “Calcolosi 2”
Abstract Presentation SC232: *"A comparison of the effectiveness of traditional and suctioning ureteral access sheath during retrograde intrarenal surgery for the treatment of renal calculi"*.
130. **Oct 2024**
SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)
Italian Society of Urology (SIU), Bari 2024
Abstract session: “Tumori dell’alta via escrettrice”
Abstract Presentation SC244: *"The impact of venous thromboembolism on upper tract urothelial carcinomas undergoing open or minimally-invasive radical nephroureterectomy in the United States: perioperative outcomes and health-care costs from insurance claims data"*.
131. **Oct 2024**
AUTHOR – 97th National Congress (This abstract has been accepted for podium presentation)
Italian Society of Urology (SIU), Bari 2024
Abstract session: “Tumore vescicale muscolo invasivo 2”
Abstract Presentation SC259: *"Risk of upper urinary tract dissemination in cT3 bladder cancer patients treated with double j stent versus nephrostomy tube prior to radical cystectomy"*.
132. **Oct 2024**
SPEAKER – 97th National Congress (This abstract has been accepted for podium presentation)
Italian Society of Urology (SIU), Bari 2024
Abstract session: “Nuove prospettive in urologia”
Abstract Presentation SC361: *"Evaluation of the effectiveness of low-intensity extracorporeal shockwave therapy (LI-ESWT) in the treatment of patients with erectile dysfunction"*.
133. **Feb 2019**

Lezioni in rete Scuole di Specializzazione in Urologia
"Sapienza" University of Rome, Department of Maternal Infant and Urologic Sciences
Title: *"Combination therapies for metastatic hormone sensitive prostate cancer (mHSPC): critical analysis of available evidences."*

134. **Oct 2020**

INVITED LECTURE – Urology Residency Program
Department of Urology, Stanford University School of Medicine
Title: *"Application of Vesical Imaging Reporting and Data System (VI-RADS): current evidences and future perspectives"*

135. **Dec 2022**

GRAND ROUND INVITED LECTURE – Urology Residency Program
"Sapienza" University of Rome, Department of Maternal Infant and Urologic Sciences
Title: *"Non-Muscle Invasive Bladder Cancer (NMIBC): part I; Adjuvant Intravesical Immunotherapy: a life-saving treatment"*

136. **Feb 2023**

GRAND ROUND INVITED LECTURE – Urology Residency Program
"Sapienza" University of Rome, Department of Maternal Infant and Urologic Sciences
Title: *"PROMLEM SOLVING: Non-Muscle Invasive Bladder Cancer (NMIBC): Management of HG T1 Bladder Cancer"*

137. **Apr 2023**

INVITED FACULTY, VIRTUAL LECTURE – Webinar SIU, L'ABC paziente uro-andrologico
Italian Society of Urology (SIU)
Title: *"ABC Neoplasia Vescicale: Gestione della terapia endocavitaria nel paziente affetto da neoplasia vescicale non-muscolo invasive"*

138. **Jul 2023**

INVITED FACULTY, VIRTUAL LECTURE – 1st International Congress
European Association of Urology (EAU) - UROonco 2023
Gothenburg, Sweden
Title: *"Role of mpMRI for management of BC"*.

139. **Sep 2023**

FACULTY INVITED PLENARY LECTURE – 29th International Congress
European Society of urogenital Radiology (ESUR) – 2023
Auditorium della Tecnica, Rome, Italy
Title: *"Spectrum of MIBC Response to Systemic Therapy"*.

140. **Nov 2023**

INVITED FACULTY – 15th International Congress
EMUC 2023 – YAU Autumn Meeting,
European Association of Urology (EAU), Marseille, France 2023

141. **May 2024**

INVITED FACULTY, LECTURE – National Congress
Trasversali in Uro-Oncologia
Ruolo del MDT nei tumori Uro-Genitali
Università di Roma, Tor Vergata
Title: *"Assessment and management in the "adequate" BCG era"*.

142. **Jun 2024**

INVITED FACULTY, PLENARY LECTURE – National Congress
Innovazione in Oncologia: Dagli ultimi Progressi alle Nuove Prospettive di Ricerca
Holiday Inn Salerno, Cava de' Tirreni

Title: *"La chirurgia del tumore della vescica: progressi e innovazioni"*.

143. **Jun 2024**

INVITED FACULTY, VIRTUAL LECTURE – Webinar SIU, L'ABC paziente uro-andrologico
Italian Society of Urology (SIU)

Title: *"UPDATE LINEE GUIDA EAU 1: Neoplasia prostatica"*

144. **Nov 2024**

INVITED FACULTY – 16th International Congress
EMUC 2024 – YAU Autumn Meeting,
European Association of Urology (EAU), Lisbon, France 2024

145. **Mar 2025**

INVITED FACULTY, PLENARY LECTURE – 40th International Congress
European Association of Urology (EAU), Madrid 2025

Title: *"Plenary Session 'Organ sparing paradigms in kidney and bladder cancer"*

1. **Jan 2020 – On-going:**

REVIEW EDITOR for the international scientific journal "Central European Journal of Urology, Polish Urological Association" since 2020. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

2. **Jan 2020 – On-going:**

REVIEW EDITOR for the international scientific journal "Minerva Urology and Nephrology" since 2020. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

3. **May 2020 – On-going:**

REVIEW EDITOR for the international scientific journal "European Urology Oncology" since 2020. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

4. **Sep 2020 – Sep 2022:**

REVIEW EDITOR for the international scientific journal "Frontiers in Urology, Urologic Oncology section" since 2020. Frontiers Media S.A. (2007-2022). The journal is indexed on: EMBASE, PubMed/MEDLINE, Scopus.

5. **Sep 2020 – Sep 2022:**

REVIEW EDITOR for the international scientific journal "Frontiers in Oncology, Genitourinary section", Frontiers Media S.A. (2007-2022) since 2020. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

6. **Sep 2020 – Sep 2022**

REVIEW EDITOR for the international scientific journal "Frontiers in Urology, Male Urology", Frontiers Media S.A. (2007 - 2022) since 2020. The journal is indexed on: EMBASE, PubMed/MEDLINE, Scopus.

7. **Oct 2020 – On-going:**

REVIEW EDITOR for the international scientific journal "Journal of Urology" since 2020. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

8. **Feb 2021 – On-going**

REVIEW EDITOR for the international scientific journal "Cancer Reports, Emerging Sources Citation Index (ESCI), Wiley" since 2021. The journal is indexed in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

9. **Apr 2021 – On-going:**

REVIEW EDITOR for the international scientific journal "International Journal of Molecular Sciences" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

10. Apr 2021 – On-going:

REVIEW EDITOR for the international scientific journal "Asian Journal of Andrology" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

11. May 2021 – On-going:

REVIEW EDITOR for the international scientific journal "Diagnostics" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

12. Jun 2021 – On-going:

REVIEW EDITOR for the international scientific journal "BMC Urology" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

13. Oct 2021 – On-going:

REVIEW EDITOR for the international scientific journal "Cancers" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

14. Oct 2021 – Oct 2022

ACADEMIC EDITOR for the international scientific journal "Disease Markers, Hindawi LTD" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

15. Oct 2021 – Feb 2022

REVIEW EDITOR for the international indexed scientific journal "Uro", ISSN 2673-4397, published by MDPI, Basel, Switzerland (1996-2022), since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE.

16. Oct 2021 – Jun 2022

REVIEW EDITOR for the international scientific journal "Andrology" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

17. Nov 2021 – Nov 2022

REVIEW EDITOR for the international scientific journal "Bladder Cancer" since 2021. The journal is indexed on: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus.

18. Jan 2022 – On-going:

ASSOCIATE EDITOR for the European Association of Urology (EAU) "UROONCO BCa Edu Platform" for the thematic session on bladder neoplasms. The UROONCO Edu platform is a topic-based educational platform with scientific and educational content in the field of Genito-Urinary Cancers, ranging from abstracts and webcasts to more interactive content such as webinars and interviews with "Key Opinion Leaders".

19. Aug 2023

ABSTRACT REVIEWER, 15th International Congress,
European Multidisciplinary Congress on Urological Cancers
EMUC 2023 – Marseille, France

20. Aug 2023

ABSTRACT REVIEWER, 16th International Congress,
European Multidisciplinary Congress on Urological Cancers
EMUC 2024 – Lisbon, Portugal

1. May 2015

CO-AUTHOR

Chapter "*Male and Female Urinary Incontinence*"

Textbook entitled: "Manuale di Urologia per studenti di Medicina"

2. Jan 2018

AUTHOR

"*Manuale di Urologia 2018*", IV Edition

Concorso Nazionale SSM 2018",

Accademia Italiana Medici Specializzandi (AIMS)

3. Jan 2019

CO-AUTHOR

Chapter: "*The Effects of Aging on Male Fertility and the Health of Offspring*".

Textbook entitled: "Comprehensive Guide to Modern Andrology".

SPOKEN LANGUAGES

- **Italian:** Mother tongue
- **Mar 2024**
English Level C1
Occupational English Test (OET) Certified
Level Cambridge C1

- **Statistical Analysis and Data Managing:**
 - Managing research projects from start to finish including data gathering, data analysis, statistical modeling, results analyzing and presentation.
 - Expertise in implementing data calculations using STATA, XLSTAT, and SPSS to generate descriptive statistical summary, categorical analyses, linear and logistic regression.
 - Data analysis expertise performing of Survival Analysis, Mixed Modeling, and Simple and Multivariable Logistic Regression.
 - Systematic Review expertise, Meta-analysis, and Meta-regressions calculations with different software including RevMan, STATA, Comprehensive Meta-analysis, Open-Metanalysis, and NCSS 2020.
- **Operating systems:**
 - Windows and MacOS
- **Office suites:**
 - Microsoft Office, G Suite
- **Presentation software:**
 - PowerPoint, Keynote
- **Spreadsheets:**
 - Excel, Google Spreadsheets, etc.
- **Communication and collaboration tools:**
 - Slack, Skype, Zoom, Meet
- **Video Editing:**
 - Final Cut Pro, Premiere Pro, iMovie
- **Graphical plotting of data analysis:**
 - Prism 8 – Graph Pad

LIST OF INTERNATIONAL PUBLICATIONS OVER THE LAST 10 YEARS (MAX n=12)

1. Cheung H, Wang Y, Chang SL, Khandwala Y, **DEL GIUDICE F**, Chung BI. Adoption of Robot-Assisted Partial Nephrectomies: A Population-Based Analysis of U.S. Surgeons from 2004 to 2013. **J Endourol**. 2017 Sep;31(9):886-892. doi: 10.1089/end.2017.0174. Epub 2017 Aug 11. PMID: 28699357
 - IMPACT FACTOR (2017): **2.038**
 - RANK BY JOURNAL CITATION INDICATOR (2017): **Q1**
 - Numero di pagine del PDF conforme all'originale: **7**
2. Antonini G, De Berardinis E, **DEL GIUDICE F**, Busetto GM, Lauretti S, Fragas R, Chung BI, Conti SL, Giannarelli D, Sperduti I, Gross MS, Perito PE. Inflatable Penile Prosthesis Placement, Scratch Technique and Postoperative Vacuum Therapy as a Combined Approach to Definitive Treatment of Peyronie's Disease. **J Urol**. 2018 Sep;200(3):642-647. doi: 10.1016/j.juro.2018.04.060. Epub 2018 Apr 17. PMID: 29678456.
 - IMPACT FACTOR (2018): **5.647**
 - RANK BY JOURNAL CITATION INDICATOR (2018): **Q1**
 - Numero di pagine del PDF conforme all'originale: **6**
3. Nicolazzo C, Busetto GM, Gradilone A, Sperduti I, **DEL GIUDICE F**, Loreni F, Cortesi E, de Berardinis E, Gazzaniga P, Raimondi C. Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. **Oncologist**. 2019 May;24(5):612-616. doi: 10.1634/theoncologist.2018-0784. Epub 2019 Apr 3. PMID: 30944184; PMCID: PMC6516110.
 - IMPACT FACTOR (2019): **5.025**
 - RANK BY JOURNAL CITATION INDICATOR (2019): **Q1**
 - Numero di pagine del PDF conforme all'originale: **5**
4. **DEL GIUDICE F**, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. **Eur Urol**. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5. PMID: 31699526.
 - IMPACT FACTOR (2020): **20.096**
 - RANK BY JOURNAL CITATION INDICATOR (2020): **Q1**
 - Numero di pagine del PDF conforme all'originale: **9**
5. **DEL GIUDICE F**, Kasman AM, De Berardinis E, Busetto GM, Belladelli F, Eisenberg ML. Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. **Fertil Steril**. 2020 Nov;114(5):984-996. doi: 10.1016/j.fertnstert.2020.04.042. Epub 2020 Jul 22. PMID: 32709378.

- IMPACT FACTOR (2020): **7.329**
 - RANK BY JOURNAL CITATION INDICATOR (2020): **Q1**
 - Numero di pagine del PDF conforme all'originale: **13**
6. **DEL GIUDICE F**, Leonardo C, Simone G, Pecoraro M, De Berardinis E, Cipollari S, Flammia S, Bicchetti M, Busetto GM, Chung BI, Gallucci M, Catalano C, Panebianco V. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? **BJU Int.** 2020 Nov;126(5):610-619. doi: 10.1111/bju.15188. Epub 2020 Aug 17. PMID: 32783347.
- IMPACT FACTOR (2020): **5.588**
 - RANK BY JOURNAL CITATION INDICATOR (2020): **Q1**
 - Numero di pagine del PDF conforme all'originale: **10**
7. Sciarra A, Viscuso P, Arditi A, Mariotti G, De Berardinis E, Di Pierro GB, Canale V, Gentilucci A, Maria Busetto G, Maggi M, Eisenberg ML, Vilson F, Chung BI, Ferro M, Salciccia S, **DEL GIUDICE F**. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review. **Int J Clin Pract.** 2021 Oct;75(10):e14208. doi: 10.1111/ijcp.14208. Epub 2021 May 4. PMID: 33811418.
- IMPACT FACTOR (2021): **3.149**
 - RANK BY JOURNAL CITATION INDICATOR (2021): **Q1**
 - Numero di pagine del PDF conforme all'originale: **12**
8. **DEL GIUDICE F**, Flammia RS, Pecoraro M, Moschini M, D'Andrea D, Messina E, Piscioti LM, De Berardinis E, Sciarra A, Panebianco V. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. **World J Urol.** 2022 Jul;40(7):1617-1628. doi: 10.1007/s00345-022-03969-6. Epub 2022 Mar 16. PMID: 35294583; PMCID: PMC9237003.
- IMPACT FACTOR (2022): **3.400**
 - RANK BY JOURNAL CITATION INDICATOR (2022): **Q1**
 - Numero di pagine del PDF conforme all'originale: **12**
9. **DEL GIUDICE F**, D'Andrea D, Pradere B, Berndt F, Pallauf M, Flammia RS, Philipp D, Moschini M, Mari A, Albisinni S, Krajewski W, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Gontero P, Shariat SF, Chung BI, Soria F. Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators. **BJU Int.** 2023 Jun;131(6):712-719. doi: 10.1111/bju.15920. Epub 2022 Nov 4. PMID: 36251366.

- IMPACT FACTOR (2023): **3.700**
 - RANK BY JOURNAL CITATION INDICATOR (2023): **Q1**
 - Numero di pagine del PDF conforme all'originale: **8**
10. **DEL GIUDICE F**, Huang J, Li S, Sorensen S, Enemchukwu E, Maggi M, Salciccia S, Ferro M, Crocetto F, Pandolfo SD, Autorino R, Krajewski W, Crivellaro S, Cacciamani GE, Bologna E, Asero V, Scornajenghi C, Moschini M, D'Andrea D, Brown DR, Chung BI. Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States. **Prostate Cancer Prostatic Dis.** 2023 Jun;26(2):367-373. doi: 10.1038/s41391-022-00558-x. Epub 2022 Jun 21. PMID: 35729329.
- IMPACT FACTOR (2023): **5.100**
 - RANK BY JOURNAL CITATION INDICATOR (2023): **Q1**
 - Numero di pagine del PDF conforme all'originale: **7**
11. **DEL GIUDICE F**, Tresh A, Li S, Basran S, Prendiville SG, Belladelli F, DE Berardinis E, Asero V, Scornajenghi CM, Carino D, Ferro M, Rocco B, Busetto GM, Falagario U, Autorino R, Crocetto F, Barone B, Pradere B, Krajewski W, Nowak Ł, Szydełko T, Moschini M, Mari A, Crivellaro S, Porpiglia F, Fiori C, Amparore D, Pichler R, Rane A, Challacombe B, Nair R, Chung BI. The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs. **Minerva Urol Nephrol.** 2024 Jun;76(3):320-330. doi: 10.23736/S2724-6051.24.05699-4. PMID: 38920012.
- IMPACT FACTOR (2023): **4.900**
 - RANK BY JOURNAL CITATION INDICATOR (2023): **Q1**
 - Numero di pagine del PDF conforme all'originale: **11**
12. Ha AS, Scott M, Zhang CA, Li S, Langroudi AP, Glover F, Basran S, **DEL GIUDICE F**, Shaw GM, Eisenberg ML. Sociodemographic Trends and Perinatal Outcomes in Fathers 50 Years and Older. **JAMA Netw Open.** 2024 Aug 1;7(8):e2425269. doi: 10.1001/jamanetworkopen.2024.25269. PMID: 39088214; PMCID: PMC11294967.
- IMPACT FACTOR (2023): **10.500**
 - RANK BY JOURNAL CITATION INDICATOR (2023): **Q1**
 - Numero di pagine del PDF conforme all'originale: **14**

LIST OF INTERNATIONAL INDEXED PUBLICATIONS "*In Extenso*" (2024 – 2014) (**SCOPUS**)

1. Busetto GM, Giovannone R, Ferro M, Tricarico S, **DEL GIUDICE F**, Matei DV, De Cobelli O, Gentile V, De Berardinis E. Chronic bacterial prostatitis: Efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). BMC Urology. 2014;14(1).
IMPACT FACTOR (2014): 1,413
2. Busetto GM, Giovannone R, Antonini G, Rossi A, **DEL GIUDICE F**, Tricarico S, Ragonesi G, Gentile V, De Berardinis E. Short-term pretreatment with a dual 5 α -reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): Evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU International. 2015;116(1):117–123.
IMPACT FACTOR (2015): 4,387
3. Chung BI, Leow JJ, Gelpi-Hammerschmidt F, Wang Y, **DEL GIUDICE F**, De S, Chou EP, Song KH, Almario L, Chang SL. Racial disparities in postoperative complications after radical nephrectomy: A population-based analysis. Urology. 2015;85(6):1411–1416.
IMPACT FACTOR (2014): 2,188
4. Giovannone R, Busetto GM, Antonini G, De Cobelli O, Ferro M, Tricarico S, **DEL GIUDICE F**, Ragonesi G, Conti SL, Lucarelli G, Gentile V, De Berardinis E. Hyperhomocysteinemia as an early predictor of erectile dysfunction: International index of erectile function (IIEF) and penile doppler ultrasound correlation with plasma levels of homocysteine. Medicine (United States). 2015;94(39):e1556.
IMPACT FACTOR (2015): 2,133
5. Antonini G, Busetto GM, De Berardinis E, Giovannone R, Vicini P, **DEL GIUDICE F**, Conti SL, Gentile V, Perito PE. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: Evaluation of efficacy, satisfaction profile and complications. International Journal of Impotence Research. 2016;28(1):4–8.
IMPACT FACTOR (2016): 1,293
6. Antonini G, Busetto GM, **DEL GIUDICE F**, Ferro M, Chung BI, Conti SL, Suarez Sarmiento A, Pacchiarotti A, De Berardinis E, Perito PE. Distal Corporal Anchoring Stitch: A Technique to Address Distal Corporal Crossovers and Impending Lateral Extrusions of a Penile Prosthesis. Journal of Sexual Medicine. 2017;14(6):767–773.
IMPACT FACTOR (2017): 3,339
7. Busetto GM, Ferro M, **DEL GIUDICE F**, Antonini G, Chung BI, Sperduti I, Giannarelli D, Lucarelli G, Borghesi M, Musi G, de Cobelli O, De Berardinis E. The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer. 2017;15(4):e661–e666.
IMPACT FACTOR (2017): 2,539
8. Cheung H, Wang Y, Chang SL, Khandwala Y, **DEL GIUDICE F**, Chung BI. Adoption of robotic

assisted partial nephrectomies: A population-based analysis of U.S. surgeons from 2004-2013. *Journal of Endourology*. 2017;31(9):886–892.

IMPACT FACTOR (2017): 2,038

9. Nicolazzo C, Busetto GM, **DEL GIUDICE F**, Sperduti I, Giannarelli D, Gradilone A, Gazzaniga P, de Berardinis E, Raimondi C. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). *Journal of Cancer Research and Clinical Oncology*. 2017;143(10):1971–1976.

IMPACT FACTOR (2017): 3,282

10. Pansadoro V, Emiliozzi P, del Vecchio G, Martini M, Scarpone P, **DEL GIUDICE F**, Veneziano D, Brassetti A, Assenmacher C. Monopolar Transurethral Enucleation of Prostatic Adenoma: Preliminary Report. *Urology*. 2017;102:252–257.

IMPACT FACTOR (2017): 2,300

11. Antonini G, De Berardinis E, **DEL GIUDICE F**, Busetto GM, Lauretti S, Fragas R, Chung BI, Conti SL, Giannarelli D, Sperduti I, Gross MS, Perito PE. Inflatable Penile Prosthesis Placement, Scratch Technique and Postoperative Vacuum Therapy as a Combined Approach to Definitive Treatment of Peyronie's Disease. *Journal of Urology*. 2018; 200(3):642–647.

IMPACT FACTOR (2018): 5,647

12. Balan D, Martha O, Chibeleian CB, Tataru S, Voidezan S, Sin A, Matei VD, Vartolomei MD, Lucarelli G, Cioffi A, **DEL GIUDICE F**, Berardinis ED, Borda A, Busetto GM, Ferro M, Pytel A, Porav-Hodade D. Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. *Medicine (United States)* . 2018;97(16).

IMPACT FACTOR (2018): 1,870

13. Busetto GM, Agarwal A, Virmani A, Antonini G, Ragonesi G, **DEL GIUDICE F**, Micic S, Gentile V, De Berardinis E. Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: A double-blind placebo-controlled study. *Andrologia* . 2018;50(3).

IMPACT FACTOR (2018): 1,840

14. Kim JH, Baek MJ, Sun HY, Lee B, Li S, Khandwala Y, **DEL GIUDICE F**, Chung BI. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-Analysis. *PLoS ONE* . 2018;13(10).

IMPACT FACTOR (2018): 2,776

15. Barchetti G, Simone G, Ceravolo I, Salvo V, Campa R, **DEL GIUDICE F**, De Berardinis E, Buccilli D, Catalano C, Gallucci M, Catto JWF, Panebianco V. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. *European Radiology*. 2019;29(10):5498–5506.

IMPACT FACTOR (2019): 4,101

16. Busetto GM, **DEL GIUDICE F**, D'Agostino D, Romagnoli D, Minervini A, Rocco B, Antonelli

A, Celia A, Schiavina R, Cindolo L, Chung BI, Kim JH, Maggi M, Sciarra A, De Berardinis E, Porreca A. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. *Archivio Italiano di Urologia e Andrologia*. 2019;19(4):205–211.

IMPACT FACTOR (2020): N/A

17. Chung KJ, Kim JH, Min GE, Park HK, Li S, **DEL GIUDICE F**, Han DH, Chung BI. Changing Trends in the Treatment of Nephrolithiasis in the Real World. *Journal of Endourology*. 2019;33(3):248–253.

IMPACT FACTOR (2019): 2,328

18. Guerri G, Maniscalchi T, Barati S, Busetto GM, **DEL GIUDICE F**, De Berardinis E, Cannarella R, Calogero AE, Bertelli M. Non-syndromic monogenic male infertility. *Acta Biomedica*. 2019;90:62–67.

IMPACT FACTOR (2019): N/A

19. Guerri G, Maniscalchi T, Barati S, Dhuli K, Busetto GM, **DEL GIUDICE F**, De Berardinis E, De Antoni L, Miertus J, Bertelli M. Syndromic infertility. *Acta Biomedica*. 2019;90:75–82.

IMPACT FACTOR (2019): N/A

20. Kim JH, Li S, Khandwala Y, **DEL GIUDICE F**, Chung KJ, Park HK, Chung BI. National trends of preoperative imaging modalities before partial nephrectomy for renal masses in the U.S. From 2007-2015. *Canadian Urological Association Journal*. 2019;13(3):E89–E94.

IMPACT FACTOR (2019): 1,372

21. Kim JH, Shim SR, Khandwala Y, **DEL GIUDICE F**, Sorensen S, Chung BI. Risk of depression after 5 alpha reductase inhibitor medication: Meta-analysis. *World Journal of Men's Health* . 2019;37.

IMPACT FACTOR (2020): 5,400

22. Maggi M, Gentilucci A, Salciccia S, Gatto A, Gentile V, Colarieti A, Von Heland M, Busetto GM, **DEL GIUDICE F**, Sciarra A. Psychological impact of different primary treatments for prostate cancer: A critical analysis. *Andrologia* . 2019;51(1).

IMPACT FACTOR (2019): 1,951

23. Nicolazzo C, Busetto GM, Gradilone A, Sperduti I, **DEL GIUDICE F**, Loreni F, Cortesi E, de Berardinis E, Gazzaniga P, Raimondi C. Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. *Oncologist*. 2019;24(5):612–616.

IMPACT FACTOR (2019): 5,025

24. Sciarra A, Gentilucci A, Silvestri I, Salciccia S, Cattarino S, Scarpa S, Gatto A, Frantellizzi V, Von Heland M, Ricciuti GP, **DEL GIUDICE F**, Maggi M. Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castration resistant prostate cancer A critical review. *Medicine (United States)* . 2019;98(19).

IMPACT FACTOR (2019): 1,552

25. Anastasi E, Maggi M, Tartaglione S, Angeloni A, Gennarini G, Leoncini PP, Sperduti I, Di Lascio G, De Stefano V, Di Pierro GB, **DEL GIUDICE F**, Busetto GM, De Berardinis E, Sciarra A. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study. *Diagnostic Cytopathology*. 2020;48(11):1034–1040.
IMPACT FACTOR (2020): 1,582

26. Antonini G, De Berardinis E, Busetto GM, **DEL GIUDICE F**, Chung BI, Conti SL, Ferro M, Musi G, Fragas R, De Cobelli O, Sperduti I, Gross MS, Perito PE. Postoperative vacuum therapy following AMSTM LGX 700® inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. *International Journal of Impotence Research*. 2020;32(1):133–139.
IMPACT FACTOR (2020): 2,896

27. Busetto GM, **DEL GIUDICE F**, Maggi M, De Marco F, Porreca A, Sperduti I, Magliocca FM, Salciccia S, Chung BI, De Berardinis E, Sciarra A. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy. *World Journal of Urology*; 2021 Jun;39(6):1869–1877.
IMPACT FACTOR (2021): 3,661

28. Busetto GM, **DEL GIUDICE F**, Maggi M, Antonini G, D'Agostino D, Romagnoli D, Del Rosso A, Giampaoli M, Corsi P, Palmer K, Ferro M, Lucarelli G, Terracciano D, De Cobelli O, Sciarra A, De Berardinis E, Porreca A. Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: A double-blind placebo-controlled trial on prostate vascularity. *Aging*. 2020;12(5):4337–4347.
IMPACT FACTOR (2020): 5,682

29. Busetto GM, **DEL GIUDICE F**, Mari A, Sperduti I, Longo N, Antonelli A, Cerruto MA, Costantini E, Carini M, Minervini A, Rocco B, Artibani W, Porreca A, Porpiglia F, Damiano R, De Sio M, Arcaniolo D, Cimino S, Russo GI, Lucarelli G, Di Tonno P, Gontero P, Soria F, Trombetta C, Liguori G, Scarpa RM, Papalia R, Terrone C, Borghesi M, Verze P, Madonia M, De Lisa A, Bove P, Guazzoni G, Lughezzani G, Racioppi M, Di Gianfrancesco L, Brunocilla E, Schiavina R, Simeone C, Veccia A, Montorsi F, Briganti A, Dal Moro F, Pavone C, Serretta V, Di Stasi SM, Galosi AB, Schips L, Marchioni M, Montanari E, Carrieri G, Cormio L, Greco F, Musi G, Maggi M, Conti SL, Tubaro A, De Berardinis E, Sciarra A, Gallucci M, Mirone V, de Cobelli O, Ferro M. How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? *Frontiers in Surgery* . 2020;7.
IMPACT FACTOR (2020): 2,718

30. Busetto GM, **DEL GIUDICE F**, Virmani A, Sciarra A, Maggi M, Ferro M, Porreca A, Chung BI, Agarwal A, De Berardinis E. Body mass index and age correlate with antioxidant supplementation effects on sperm quality: Post hoc analyses from a double-blind placebo-controlled trial. *Andrologia* . 2020;52(3).
IMPACT FACTOR (2020): 2,775

31. Busetto GM, Porreca A, **DEL GIUDICE F**, Maggi M, D'Agostino D, Romagnoli D, Musi G, Lucarelli G, Palmer K, Colonna Di Paliano A, Muto M, Hurle R, Terracciano D, De Cobelli O, Sciarra A, De Berardinis E, Ferro M. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features. *Urologia Internationalis*. 2020;104(7–8):510–522.
IMPACT FACTOR (2020): 2,718

32. **DEL GIUDICE F**, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. *European Urology*. 2020;77(1):101–109.
IMPACT FACTOR (2020): 20,096

33. **DEL GIUDICE F**, Busetto G, De Berardinis E, Sperduti I, Ferro M, Maggi M, Gross M, Sciarra A, Eisenberg M. A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. *Asian Journal of Andrology*. 2020;22(4):360–367.
IMPACT FACTOR (2020): 3,285

34. **DEL GIUDICE F**, Campa R, Bicchetti M, de Berardinis E, Panebianco V. Vesical imaging-reporting and data system (VI-RADS) incorporated into bladder cancer clinical practice: What's the perspectives beyond diagnostic accuracy? *Translational Andrology and Urology*. 2020;9(5):2320–2322.
IMPACT FACTOR (2020): 3,150

35. **DEL GIUDICE F**, Catto JWF, Panebianco V. Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. *Eur Urol* 2020;77:101–9. *European Urology*. 2020;77(4):e94–e95.
IMPACT FACTOR (2020): 20,096

36. **DEL GIUDICE F**, Kasman AM, De Berardinis E, Busetto GM, Belladelli F, Eisenberg ML. Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. *Fertility and Sterility*. 2020;114(5):984–996.
IMPACT FACTOR (2020): 7,329

37. **DEL GIUDICE F**, Kasman AM, Ferro M, Sciarra A, De Berardinis E, Belladelli F, Salonia A, Eisenberg ML. Clinical correlation among male infertility and overall male health: A systematic review of the literature. *Investigative and Clinical Urology*. 2020;61(4):355–371.
IMPACT FACTOR (2020): 2,186

38. **DEL GIUDICE F**, Leonardo C, Simone G, Pecoraro M, De Berardinis E, Cipollari S, Flammia S, Bicchetti M, Busetto GM, Chung BI, Gallucci M, Catalano C, Panebianco V. Preoperative

detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU International. 2020;126(5):610–619.

IMPACT FACTOR (2020): 5,588

39. **DEL GIUDICE F**, Pecoraro M, Vargas HA, Cipollari S, De Berardinis E, Bicchetti M, Chung BI, Catalano C, Narumi Y, Catto JWF, Panebianco V. Systematic review and meta-analysis of vesical imaging-reporting and data system (Vi-rads) inter-observer reliability: An added value for muscle invasive bladder cancer detection. Cancers. 2020;12(10):1–17.

IMPACT FACTOR (2020): 6,639

40. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, **DEL GIUDICE F**, Damiano R, Perri F, Perdonà S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, Shariat S, Sonpavde G, Buonerba C. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World Journal of Urology. 2020;38(1):143–150.

IMPACT FACTOR (2020): 4,226

41. Ferro M, Katalin MO, Buonerba C, Marian R, Cantiello F, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, **DEL GIUDICE F**, Perdonà S, Del Prete P, Mirone V, Borghesi M, Porreca A, Artibani W, Bove P, Lima E, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Ditunno P, Serretta V, Russo GI, Terracciano D, di Lorenzo G, Damiano R, Sonpavde G, Vartolomei MD, de Cobelli O, Lucarelli G. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations. 2020;38(5):459–464.

IMPACT FACTOR (2020): 3,498

42. Ferro M, Lucarelli G, de Cobelli O, Vartolomei MD, Damiano R, Cantiello F, Crocerossa F, Perdonà S, Del Prete P, Cordima G, Musi G, **DEL GIUDICE F**, Busetto GM, Chung BI, Porreca A, Ditunno P, Battaglia M, Terracciano D. Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World Journal of Urology . 2021 Jun;39(6):1861–1867.

IMPACT FACTOR (2021): 3,661

43. Flammia S, Frisenda M, Maggi M, Magliocca FM, Ciardi A, Panebianco V, De Berardinis E, Salciccia S, Battista Di Pierro G, Gentilucci A, **DEL GIUDICE F**, Busetto GM, Gallucci M, Sciarra A. Cribriform pattern does not have a significant impact in Gleason Score ≥ 7 /ISUP Grade ≥ 2 prostate cancers submitted to radical prostatectomy. Medicine (United States). 2020;99(38):E22156.

IMPACT FACTOR (2020): 1,889

44. Giganti F, Pecoraro M, Fierro D, Campa R, **DEL GIUDICE F**, Punwani S, Kirkham A, Allen C, Emberton M, Catalano C, Moore CM, Panebianco V. DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations. *Magnetic Resonance Imaging*. 2020;67:50–58.

IMPACT FACTOR (2020): 2,546

45. Kasman A, **DEL GIUDICE F**, Shkolyar E, Porreca A, Busetto GM, Lu Y, Eisenberg ML. Modeling the contribution of the obesity epidemic to the temporal decline in sperm counts. *Archivio Italiano di Urologia e Andrologia*. 2020;92(4):357–361.

IMPACT FACTOR (2020): N/A

46. Kasman AM, **DEL GIUDICE F**, Eisenberg ML. New insights to guide patient care: the bidirectional relationship between male infertility and male health. *Fertility and Sterility*. 2020;113(3):469–477.

IMPACT FACTOR (2020): 7,329

47. Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G, Busetto GM, Barchetti G, Campa R, Sperduti I, **DEL GIUDICE F**, Sciarra A. Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology Focus*. 2020;6(3):463–478.

IMPACT FACTOR (2020): 5,996

48. Panebianco V, **DEL GIUDICE F**, Leonardo C, Sciarra A, Catalano C, Catto JWF. VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. *European Urology*. 2020;78(1):e18–e20.

IMPACT FACTOR (2020): 20,096

49. Porreca A, **DEL GIUDICE F**, Giampaoli M, D'Agostino D, Romagnoli D, Corsi P, Del Rosso A, Maggi M, Chung BI, Ferro M, De Cobelli O, Lucarelli G, Schiavina R, De Berardinis E, Sciarra A, Busetto GM, Roviello G. Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study. *Medicine (United States)*. 2020;99(37):E22059.

IMPACT FACTOR (2020): 1,889

50. Salciccia S, **DEL GIUDICE F**, Eisenberg ML, Mastroianni CM, De Berardinis E, Ricciuti GP, Maggi M, Sciarra A. Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone. *Therapeutic Advances in Endocrinology and Metabolism*. 2020;11.

IMPACT FACTOR (2020): 3,565

51. Salciccia S, **DEL GIUDICE F**, Gentile V, Mastroianni CM, Pasculli P, Di Lascio G, Ciardi MR, Sperduti I, Maggi M, De Berardinis E, Eisenberg ML, Sciarra A. Interplay between male

testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission. *Endocrine*. 2020;70(2):206–210.

IMPACT FACTOR (2020): 3,633

52. Sciarra A, Salciccia S, Maggi M, **DEL GIUDICE F**, Busetto GM, Musio D, Ciardi A, Catalano C, Cortesi E, Panebianco V. Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience. *Prostate Cancer and Prostatic Diseases*. 2020;23(3):407–409.

IMPACT FACTOR (2020): 5,554

53. Woo S, Panebianco V, Narumi Y, **DEL GIUDICE F**, Muglia VF, Takeuchi M, Ghafoor S, Bochner BH, Goh AC, Hricak H, Catto JWF, Vargas HA. Corrigendum to “Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis” [*European Urology Oncology* 3 (2020) 306-315. *European urology oncology*. 2020;3(6):811.

IMPACT FACTOR (2020): 7,479

54. Woo S, Panebianco V, Narumi Y, **DEL GIUDICE F**, Muglia VF, Takeuchi M, Ghafoor S, Bochner BH, Goh AC, Hricak H, Catto JWF, Vargas HA. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. *European urology oncology*. 2020;3(3):306–315.

IMPACT FACTOR (2020): 7,479

55. Annese P, d’Altilia N, Mancini V, Falagario UG, **DEL GIUDICE F**, Ferro M, de Cobelli O, Porreca A, Busetto GM, Carrieri G. Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center. *Therapeutic Advances in Urology* . 2021;13.

IMPACT FACTOR (2021): 3,130

56. Belladelli F, **DEL GIUDICE F**, Kasman A, Kold Jensen T, Jørgensen N, Salonia A, Eisenberg ML. The association between cannabis use and testicular function in men: A systematic review and meta-analysis. *Andrology*. 2021;9(2):503–510.

IMPACT FACTOR (2021): 4,456

57. Belladelli F, **DEL GIUDICE F**, Kasman A, Salonia A, Eisenberg ML. The association between testosterone, estradiol and their ratio and mortality among US men. *Andrologia*. 2021;53(4).

IMPACT FACTOR (2021): 2,532

58. Bruno SM, Falagario UG, d’Altilia N, Recchia M, Mancini V, Selvaggio O, Sanguedolce F, **DEL GIUDICE F**, Maggi M, Ferro M, Porreca A, Sciarra A, De Berardinis E, Bettocchi C, Busetto GM, Cormio L, Carrieri G. PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. *Frontiers in Oncology* . 2021;11.

IMPACT FACTOR (2021): 5,738

59. **DEL GIUDICE F**, Busetto GM, Gross MS, Maggi M, Sciarra A, Salciccia S, Ferro M, Sperduti

I, Flammia S, Canale V, Chung BI, Conti SL, Eisenberg ML, Skinner EC, De Berardinis E. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. *Journal of Cancer Research and Clinical Oncology*. 2021;147(10):3073–3080.

IMPACT FACTOR (2021): 4,322

60. **DEL GIUDICE F**, D'andrea D, Mari A, Soria F, Krajewski W, Moschini M. Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration? *Minerva Urology and Nephrology*. 2021;73(5):674–676.

IMPACT FACTOR (2021): 5,214

61. **DEL GIUDICE F**, Eisenberg ML. Does semen analysis testing reveal disparities? *Nature Reviews Urology*. 2021;18(9):515.

IMPACT FACTOR (2021): 16,430

62. **DEL GIUDICE F**, Glover F, Belladelli F, De Berardinis E, Sciarra A, Salciccia S, Kasman AM, Chen T, Eisenberg ML. Association of daily step count and serum testosterone among men in the United States. *Endocrine*. 2021;72(3):874–881.

IMPACT FACTOR (2021): 3,925

63. **DEL GIUDICE F**, Kasman AM, Chen T, De Berardinis E, Busetto GM, Sciarra A, Ferro M, Lucarelli G, Belladelli F, Salonia A, Eisenberg ML. The Association between Mortality and Male Infertility: Systematic Review and Meta-analysis. *Urology*. 2021;154:148–157.

IMPACT FACTOR (2021): 2,633

64. **DEL GIUDICE F**, Kasman AM, Eisenberg ML. AUTHOR REPLY. *Urology*. 2021;147:148–149.

IMPACT FACTOR (2021): 2,633

65. **DEL GIUDICE F**, Kasman AM, Li S, Belladelli F, Ferro M, de Cobelli O, De Berardinis E, Busetto GM, Eisenberg ML. Increased Mortality Among Men Diagnosed With Impaired Fertility: Analysis of US Claims Data. *Urology*. 2021;147:143–149.

IMPACT FACTOR (2021): 2,633

66. Ferro M, Babă DF, Cobelli OD, Musi G, Lucarelli G, Terracciano D, Porreca A, Busetto GM, **DEL GIUDICE F**, Soria F, Gontero P, Cantiello F, Damiano R, Rocco P, Scarpa RM, Abu Farhan AR, Autorino R, Brescia A, Marchioni M, Mari A, Minervini A, Longo N, Chiancone F, Perdoni S, Barone B, Placido PD, Catellani M, Bottero D, Ditunno P, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Smelzo S, Hurle R, Crisan N, Manfredi M, Porpiglia F, Crocetto F, Buonerba C, Danilescu A, Vartolomei MD. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. *Future Science OA* . 2021;7(7).

IMPACT FACTOR (2021): N/A

67. Ferro M, de Cobelli O, Musi G, Lucarelli G, Terracciano D, Pacella D, Muto T, Porreca A, Busetto GM, **DEL GIUDICE F**, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Farhan ARA, Autorino R, Vartolomei MD, Muto M, Marchioni M, Mari A, Scafuri L, Minervini A, Longo N, Chiancone F, Perdona S, De Placido P, Verde A, Catellani M, Luzzago S, Mistretta FA, Ditunno P, Caputo VF, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Di Lorenzo G, Crocetto F, Buonerba C. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. *Frontiers in Oncology* . 2021;11.
IMPACT FACTOR (2021): 5,738
68. Ferro M, de Cobelli O, Vartolomei MD, Lucarelli G, Crocetto F, Barone B, Sciarra A, **DEL GIUDICE F**, Muto M, Maggi M, Carrieri G, Busetto GM, Falagario U, Terracciano D, Cormio L, Musi G, Tataru OS. Prostate cancer radiogenomics—from imaging to molecular characterization. *International Journal of Molecular Sciences* . 2021;22(18).
IMPACT FACTOR (2021): 6,208
69. Ferro M, **DEL GIUDICE F**, Carrieri G, Busetto GM, Cormio L, Hurle R, Contieri R, Arcaniolo D, Sciarra A, Maggi M, Porpiglia F, Manfredi M, Fiori C, Antonelli A, Tafuri A, Bove P, Terrone C, Borghesi M, Costantini E, Iliano E, Montanari E, Boeri L, Russo GI, Madonia M, Tedde A, Veccia A, Simeone C, Liguori G, Trombetta C, Brunocilla E, Schiavina R, Dal Moro F, Racioppi M, Vartolomei MD, Longo N, Spirito L, Crocetto F, Cantiello F, Damiano R, Di Stasi SM, Marchioni M, Schips L, Parma P, Carmignani L, Conti A, Soria F, Gontero P, Barone B, Deho F, Zaffuto E, Papalia R, Scarpa RM, Pagliarulo V, Lucarelli G, Ditunno P, Botticelli FMG, Musi G, Catellani M, de Cobelli O. The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis. *Cancers* . 2021;13(21).
IMPACT FACTOR (2021): 6,575
70. Ferro M, Di Mauro M, Cimino S, Morgia G, Lucarelli G, Abu Farhan AR, Vartolomei MD, Porreca A, Cantiello F, Damiano R, Busetto GM, **DEL GIUDICE F**, Hurle R, Perdonà S, Borghesi M, Bove P, Autorino R, Crisan N, Marchioni M, Schips L, Soria F, Mari A, Minervini A, Veccia A, Battaglia M, Terracciano D, Musi G, Cordima G, Muto M, Mirone V, de Cobelli O, Russo GI. Systemic combining inflammatory score (SCIS): A new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. *Translational Andrology and Urology*. 2021;10(2):626–635.
IMPACT FACTOR (2021): 2,479
71. Ferro M, La Civita E, Liotti A, Cennamo M, Tortora F, Buonerba C, Crocetto F, Lucarelli G, Busetto GM, **DEL GIUDICE F**, de Cobelli O, Carrieri G, Porreca A, Cimmino A, Terracciano D. Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer. *Journal of Personalized Medicine* . 2021;11(3).
IMPACT FACTOR (2021): 3,508
72. Ferro M, Lucarelli G, De Cobelli O, Dolce P, Terracciano D, Musi G, Porreca A, Busetto GM,

DEL GIUDICE F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Abu Farhan AR, Autorino R, Vartolomei MD, Marchioni M, Mari A, Minervini A, Longo N, Celentano G, Chiancone F, Perdonà S, Del Prete P, Ditunno P, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Ribera D, De Placido P, Facchini S, Scafuri L, Verde A, Di Lorenzo G, Cosimato V, Luciano A, Caputo VF, Crocetto F, Buonerba C. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. *Future Oncology*. 2021;17(30):3987–3994.

IMPACT FACTOR (2021): 3,674

73. Ferro M, Lucarelli G, de Cobelli O, **DEL GIUDICE F**, Musi G, Mistretta FA, Luzzago S, Busetto GM, Buonerba C, Sciarra A, Conti S, Porreca A, Battaglia M, Ditunno P, Manfredi M, Fiori C, Porpiglia F, Terracciano D. The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: The perspective through bibliometric analysis of an Italian translational working group in uro-oncology. *Minerva Urology and Nephrology*. 2021;73(4):442–451.

IMPACT FACTOR (2021): 5,214

74. Ferro M, Musi G, Matei DV, Mistretta AF, Luzzago S, Cozzi G, Bianchi R, Di Trapani E, Cioffi A, Lucarelli G, Busetto GM, **DEL GIUDICE F**, Russo GI, Di Mauro M, Porreca A, Renne G, Catellani M, Bottero D, Brescia A, Cordima G, de Cobelli O. Assessment of psim (Prostatic systemic inflammatory markers) score in predicting pathologic features at robotic radical prostatectomy in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. *Diagnostics* . 2021;11(2).

IMPACT FACTOR (2021): 3,992

75. KIANI AK, PAOLACCI S, CALOGERO AE, CANNARELLA R, DI RENZO GC, GERLI S, DELLA MORTE C, BUSETTO GM, DE BERARDINIS E, **DEL GIUDICE F**, STUPPIA L, FACCHINETTI F, DINICOLA S, BERTELLI M. From Myo-inositol to D-chiro-inositol molecular pathways. *European Review for Medical and Pharmacological Sciences*. 2021;25(5):2390–2402.

IMPACT FACTOR (2021): N/A

76. Maggi M, **DEL GIUDICE F**, Falagario UG, Cocci A, Russo GI, Di Mauro M, Sepe GS, Galasso F, Leonardi R, Iacona G, Carroll PR, Cooperberg MR, Porreca A, Ferro M, Lucarelli G, Terracciano D, Cormio L, Carrieri G, De Berardinis E, Sciarra A, Busetto GM. Selectmdx and multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy: A prospective assessment in a multi-institutional study. *Cancers* . 2021;13(9).

IMPACT FACTOR (2021): 6,575

77. Maggi M, Salciccia S, **DEL GIUDICE F**, Busetto GM, Falagario UG, Carrieri G, Ferro M, Porreca A, Di Pierro GB, Fasulo V, Frantellizzi V, De Vincentis G, De Berardinis E, Sciarra A. A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data. *Frontiers in Oncology* . 2021;11.

IMPACT FACTOR (2021): 5,738

78. Nowak Ł, Krajewski W, Chorbińska J, Kiełb P, Sut M, Moschini M, Teoh JYC, Mori K, **DEL GIUDICE F**, Laukhtina E, Lonati C, Kaliszewski K, Małkiewicz B, Szydełko T. The impact of diagnostic ureteroscopy prior to radical nephroureterectomy on oncological outcomes in patients with upper tract urothelial carcinoma: A comprehensive systematic review and meta-analysis. *Journal of Clinical Medicine* . 2021;10(18).
IMPACT FACTOR (2021): 4,964
79. Panebianco V, **DEL GIUDICE F**, Narumi Y, Simone G, De Berardinis E, Catto JWF. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. *Eur Urol* 2020; 77:636–43. *Eur Urol* 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? *Eur Urol* 2021;79:e35–e36. *European Urology*. 2021;79(2):e52–e53.
IMPACT FACTOR (2021): 24,344
80. Porreca A, Bianchi FM, Salvaggio A, D'Agostino D, Del Rosso A, Romagnoli D, Corsi P, Colicchia M, Barbaresi U, Bianchi L, Giampaoli M, Schiavina R, Palmer K, **DEL GIUDICE F**, Maggi M, Ferro M, Sciarra A, De Berardinis E, Busetto GM. Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions. *World Journal of Urology*. 2021;39(5):1473–1479.
IMPACT FACTOR (2021): 3,661
81. Porreca A, D'Agostino D, Romagnoli D, **DEL GIUDICE F**, Maggi M, Palmer K, Falabella R, De Berardinis E, Sciarra A, Ferro M, Artibani W, Mirone V, Busetto GM. The Clinical Efficacy of Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults: A Systematic Review of Randomized Control Trials. *Urologia Internationalis*. 2021;105(7):531–540.
IMPACT FACTOR (2021): 1,934
82. Salciccia S, Capriotti AL, Laganà A, Fais S, Logozzi M, De Berardinis E, Busetto GM, Di Pierro GB, Ricciuti GP, **DEL GIUDICE F**, Sciarra A, Carroll PR, Cooperberg MR, Sciarra B, Maggi M. Biomarkers in prostate cancer diagnosis: From current knowledge to the role of metabolomics and exosomes. *International Journal of Molecular Sciences* . 2021;22(9).
IMPACT FACTOR (2021): 6,208
83. Salciccia S, **DEL GIUDICE F**, Eisenberg ML, Mastroianni CM, De Berardinis E, Ricciuti GP, Viscuso P, Zingaropoli A, Pasculli P, Ciardi MR, Sciarra A, Maggi M. Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection. *Therapeutic Advances in Endocrinology and Metabolism* . 2021;12.
IMPACT FACTOR (2021): 4,435
84. Salciccia S, **DEL GIUDICE F**, Maggi M, Eisenberg ML, Chung BI, Conti SL, Kasman AM, Vilson FL, Ferro M, Lucarelli G, Viscuso P, Di Pierro G, Busetto GM, Luzi M, Sperduti I, Ricciuti GP, De Berardinis E, Sciarra A. Safety and feasibility of outpatient surgery in benign prostatic hyperplasia: A systematic review and meta-Analysis. *Journal of Endourology*.

2021;35(4):395–408.

IMPACT FACTOR (2021): 2,619

85. Salciccia S, Eisenberg ML, Maggi M, Lai S, Mastroianni CM, Pasculli P, Ciardi MR, Canale V, Ferro M, Busetto GM, De Berardinis E, Ricciuti GP, Sciarra A, DEL GIUDICE F. Modeling the contribution of male testosterone levels to the duration of positive covid testing among hospitalized male covid-19 patients. *Diagnostics* . 2021;11(4).

IMPACT FACTOR (2021): 3,992

86. Salciccia S, Rosati D, Viscuso P, Canale V, Scarrone E, Frisenda M, Catuzzi R, Moriconi M, Asero V, Signore S, De Dominicis M, Emiliozzi P, Carbone A, Pastore AL, Fuschi A, Di Pierro GB, Gentilucci A, Cattarino S, Mariotti G, Busetto GM, Ferro M, De Berardinis E, Ricciuti GP, Panebianco V, Magliocca FM, DEL GIUDICE F, Maggi M, Sciarra A. Influence of operative time and blood loss on surgical margins and functional outcomes for laparoscopic versus robotic-assisted radical prostatectomy: a prospective analysis. *Central European Journal of Urology*. 2021;74(4):503–515.

IMPACT FACTOR (2021): N/A

87. Sciarra A, Busetto GM, Salciccia S, DEL GIUDICE F, Maggi M, Crocetto F, Ferro M, De Berardinis E, Scarpa RM, Porpiglia F, Carmignani L, Damiano R, Artibani W, Carrieri G. Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies. *Frontiers in Endocrinology* . 2021;12.

IMPACT FACTOR (2021): 6,055

88. Sciarra A, Di Lascio G, DEL GIUDICE F, Leoncini PP, Salciccia S, Gentilucci A, Porreca A, Chung BI, Pierro GD, Busetto GM, De Berardinis E, Maggi M. Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: A systematic review. *Current Urology*. 2021;15(1):22–32.

IMPACT FACTOR (2021): N/A

89. Sciarra A, Frisenda M, Maggi M, Magliocca FM, Ciardi A, Panebianco V, De Berardinis E, Salciccia S, Di Pierro GB, Gentilucci A, DEL GIUDICE F, Busetto GM, Tufano A. Prospective comparative trial on nerve-sparing radical prostatectomy using a robot-assisted versus laparoscopic technique: Expectation versus satisfaction and impact on surgical margins. *Central European Journal of Urology*. 2021;74(2):169–177.

IMPACT FACTOR (2021): N/A

90. Sciarra A, Maggi M, Proposto AD, Magliocca FM, Ciardi A, Panebianco V, de Berardinis E, Salciccia S, Di Pierro GB, Gentilucci A, Kasman AM, Chung BI, Ferro M, de Cobelli O, DEL GIUDICE F, Busetto GM, Gallucci M, Frisenda M. Impact of uni- or multifocal perineural invasion in prostate cancer at radical prostatectomy. *Translational Andrology and Urology*. 2021;10(1):66–76.

IMPACT FACTOR (2021): 2,479

91. Sciarra A, Viscuso P, Arditi A, Mariotti G, De Berardinis E, Di Pierro GB, Canale V, Gentilucci A, Maria Busetto G, Maggi M, Eisenberg ML, Vilson F, Chung BI, Ferro M, Salciccia S, DEL

GIUDICE F. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review. *International Journal of Clinical Practice* . 2021;75(10).

IMPACT FACTOR (2021): 3,149

92. Tătaru OS, Vartolomei MD, Rassweiler JJ, Virgil O, Lucarelli G, Porpiglia F, Amparore D, Manfredi M, Carrieri G, Falagario U, Terracciano D, de Cobelli O, Busetto GM, **DEL GIUDICE F.**, Ferro M. Artificial intelligence and machine learning in prostate cancer patient management—current trends and future perspectives. *Diagnostics* . 2021;11(2).

IMPACT FACTOR (2021): 3,992

93. Afferi L, Gallioli A, **DEL GIUDICE F.**, Pradere B, Soria F, Moschini M. Comment on “Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis” on behalf of the Young Academic Urologists – Urothelial Cancer Working Group. *Minerva Urology and Nephrology*. 2022;74(6):813–815.

IMPACT FACTOR (2022): 4,900

94. Aveta A, Cacciapuoti C, Barone B, Di Zazzo E, **DEL GIUDICE F.**, Maggi M, Ferro M, Terracciano D, Busetto GM, Lucarelli G, Tataru OS, Montanari E, Mirto BF, Falcone A, Giampaglia G, Sicignano E, Capone F, Villano G, Angellotto P, Manfredi C, Napolitano L, Imbimbo C, Pandolfo SD, Crocetto F. The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk? *Cancers* . 2022;14(19).

IMPACT FACTOR (2022): 5,200

95. Belladelli F, Chen T, Basran S, Greenberg DR, **DEL GIUDICE F.**, Mulloy E, Chen CH, Cheng YS, Salonia A, Eisenberg ML. The Association between Monthly, Yearly, and Lifetime Cannabis Use, and Semen Parameters in Asian-American Men. *World Journal of Men's Health* . 2022;40.

IMPACT FACTOR (2022): 4,800

96. Belladelli F, **DEL GIUDICE F.**, Eisenberg ML. In Defense of Phosphodiesterase 5 Inhibitors. *JAMA Ophthalmology*. 2022;140(9):908

IMPACT FACTOR (2022): 8,100

97. Bicchetti M, Simone G, Giannarini G, Girometti R, Briganti A, Brunocilla E, Cardone G, De Cobelli F, Gaudio C, **DEL GIUDICE F.**, Flammia S, Leonardo C, Pecoraro M, Schiavina R, Catalano C, Panebianco V. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. *Radiologia Medica*. 2022;127(8):881–890.

IMPACT FACTOR (2022): 8,900

98. Busetto GM, D'Agostino D, Colicchia M, Palmer K, Artibani W, Antonelli A, Bianchi L, Bocciardi A, Brunocilla E, Carini M, Carrieri G, Cormio L, Falagario UG, De Berardinis E, Sciarra A, Leonardo C, **DEL GIUDICE F.**, Maggi M, de Cobelli O, Ferro M, Musi G, Ercolino A, Di Maida F, Gallina A, Introini C, Mearini E, Cochetti G, Minervini A, Montorsi F, Schiavina

R, Serni S, Simeone C, Parma P, Serao A, Mangano MS, Pomara G, Ditunno P, Simonato A, Romagnoli D, Crestani A, Porreca A. Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy Registry. *Frontiers in Oncology* . 2022;12.

IMPACT FACTOR (2022): 4,700

99. Chen T, Belladelli F, **DEL GIUDICE F**, Eisenberg ML. Male fertility as a marker for health. *Reproductive BioMedicine Online*. 2022;44(1):131–144.

IMPACT FACTOR (2022): 4,000

100. Cimadamore A, Teoh JY, Di Trapani E, Krajewski W, Tan WS, Mori K, **DEL GIUDICE F**, Carrion DM, Moschini M. A gender-related dichotomy in bladder cancer. *Minerva Urology and Nephrology*. 2022;74(3):376–378.

IMPACT FACTOR (2022): 4,900

101. D'Andrea D, Shariat SF, Soria F, Mari A, Mertens LS, Di Trapani E, Carrion DM, Pradere B, Pichler R, Filippot R, Grisay G, **DEL GIUDICE F**, Laukhtina E, Paulnsteiner D, Krajewski W, Vallet S, Maggi M, De Berardinis E, Álvarez-Maestro M, Brönmann S, Di Maida F, van Rhijn BWG, Hendricksen K, Moschini M. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. *European Urology Open Science*. 2022;41:74–80.

IMPACT FACTOR (2022): 2,500

102. d'Altillia N, Mancini V, Falagario UG, Martino L, Di Nauta M, Calò B, **DEL GIUDICE F**, Basran S, Chung BI, Porreca A, Bianchi L, Schiavina R, Brunocilla E, Busetto GM, Bettocchi C, Annese P, Cormio L, Carrieri G. A Matched-Pair Analysis after Robotic and Retropubic Radical Prostatectomy: A New Definition of Continence and the Impact of Different Surgical Techniques. *Cancers* . 2022;14(18).

IMPACT FACTOR (2022): 5,200

103. **DEL GIUDICE F**, Belladelli F, Chen T, Glover F, Mulloy EA, Kasman AM, Sciarra A, Salciccia S, Canale V, Maggi M, Ferro M, Busetto GM, De Berardinis E, Salonia A, Eisenberg ML. The association of impaired semen quality and pregnancy rates in assisted reproduction technology cycles: Systematic review and meta-analysis. *Andrologia* . 2022;54(6).

IMPACT FACTOR (2022): 2,400

104. **DEL GIUDICE F**, Chung BI, Moschini M, Mari A, D'Andrea D, Soria F, Krajewski W, Gallioli A, De Berardinis E, Maggi M. Comment on: Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: Comparison with standard management in a high-volume center and Trifecta proposal. *Minerva Urology and Nephrology*. 2022;74(1):119–121.

IMPACT FACTOR (2022): 4,900

105. **DEL GIUDICE F**, Flammia RS, Chung BI, Moschini M, Pradere B, Mari A, Soria F, Albisinni S, Krajewski W, Szydełko T, Laukhtina E, D'Andrea D, Gallioli A, Mertens LS, Maggi M, Sciarra A, Salciccia S, Ferro M, Scornajenghi CM, Asero V, Cattarino S, Angelis MD,

Cacciamani GE, Autorino R, Pandolfo SD, Falagario UG, D'Altilla N, Mancini V, Chirico M, Cinelli F, Bettocchi C, Cormio L, Carrieri G, De Berardinis E, Busetto GM. Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. *Cancers* . 2022;14(4).

IMPACT FACTOR (2022): 5,200

106. **DEL GIUDICE F**, Flammia RS, Pecoraro M, Moschini M, D'Andrea D, Messina E, Piscioti LM, De Berardinis E, Sciarra A, Panebianco V. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. *World Journal of Urology*. 2022;40(7):1617–1628.

IMPACT FACTOR (2022): 3,400

107. **DEL GIUDICE F**, Oh JK, Basran S, Nicaise E, Song PH, Kim W, Kim SY, Min GE, Yoo KH, Cho HJ, Lee S, Sciarra A, Salciccia S, De Berardinis E, Asero V, Scornajenghi CM, Pradere B, Krajewski W, Gallioli A, Ferro M, Crocetto F, Pandolfo SD, Autorino R, Belladelli F, Mari A, Busetto GM, Li S, Crivellaro S, Chung BI. Recent Trends in the Diagnostic and Surgical Management of Benign Prostatic Hyperplasia in the U.S. from 2004 to 2017: Annual Changes in the Selection of Treatment Options and Medical Costs. *Applied Sciences (Switzerland)* . 2022;12(17).

IMPACT FACTOR (2022): 2,700

108. **DEL GIUDICE F**, van Uem S, Li S, Vilson FL, Sciarra A, Salciccia S, Busetto GM, Maggi M, Tiberia L, Viscuso P, Canale V, Panebianco V, Pecoraro M, Ferro M, Moschini M, Krajewski W, D'Andrea D, Cacciamani GE, Mari A, Soria F, Porpiglia F, Fiori C, Amparore D, Checcucci E, Autorino R, De Berardinis E, Chung BI. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. *Clinical Genitourinary Cancer*. 2022;20(2):198.e1-198.e9.

IMPACT FACTOR (2022): 3,200

109. **DEL GIUDICE F**, Yoo KH, Lee S, Oh JK, Cho HJ, Kim SY, Min GE, Lee SH, Kim W, Li S, Wei W, Huang J, Brown DR, Spradling K, Basran S, Belladelli F, Autorino R, Pandolfo SD, Crivellaro S, Crocetto F, Ferro M, Asero V, Scornajenghi CM, Bologna E, Sciarra A, Salciccia S, De Berardinis E, Ricciuti GP, van Uem S, Conti S, Chung BI. Characteristics of Sepsis or Acute Pyelonephritis Combined with Ureteral Stone in the United States: A Retrospective Analysis of Large National Cohort. *Applied Sciences (Switzerland)* . 2022;12(21).

IMPACT FACTOR (2022): 2,700

110. Del Monte M, Cipollari S, **DEL GIUDICE F**, Pecoraro M, Bicchetti M, Messina E, Dehghanpour A, Ciardi A, Sciarra A, Catalano C, Panebianco V. MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques. *British Journal of Radiology* . 2022;95(1131).

IMPACT FACTOR (2022): 2,800

111. Di Lascio G, Sciarra A, DEL GIUDICE F, Salciccia S, Busetto GM, De Berardinis E, Ricciuti GP, Castellani D, Pirola GM, Maggi M, Gentilucci A, Cattarino S, Mariotti G, Casale P, Di Pierro GB. Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review. *Central European Journal of Urology*. 2022;75(1):14–27.
IMPACT FACTOR (2022): 1,200
112. Ferro M, Barone B, Crocetto F, Lucarelli G, Busetto GM, DEL GIUDICE F, Maggi M, Crocerossa F, Cantiello F, Damiano R, Borghesi M, Bove PL, Papalia R, Mari A, Luzzago S, Soria F, Marchioni M, La Civita E, Terracciano D, Mistretta FA, Piccinelli M, Marmioli A, Russo GI, Schips L, Hurle R, Contieri R, Perdonà S, Del Prete P, Mirone V, Tataru OS, Musi G, Montanari E, de Cobelli O, Vartolomei MD. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*. 2022;40(11):490.e13–490.e20.
IMPACT FACTOR (2022): 2,700
113. Ferro M, Chiujea S, Musi G, Lucarelli G, DEL GIUDICE F, Hurle R, Damiano R, Cantiello F, Mari A, Minervini A, Busetto GM, Carrieri G, Crocetto F, Barone B, Caputo VF, Cormio L, Ditunno P, Sciarra A, Terracciano D, Cioffi A, Luzzago S, Piccinelli M, Mistretta FA, Vartolomei MD, de Cobelli O. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. *Clinical Genitourinary Cancer*. 2022;20(2):e166–e172.
IMPACT FACTOR (2022): 3,200
114. Ferro M, de Cobelli O, Musi G, DEL GIUDICE F, Carrieri G, Busetto GM, Falagario UG, Sciarra A, Maggi M, Crocetto F, Barone B, Caputo VF, Marchioni M, Lucarelli G, Imbimbo C, Mistretta FA, Luzzago S, Vartolomei MD, Cormio L, Autorino R, Tătaru OS. Radiomics in prostate cancer: an up-to-date review. *Therapeutic Advances in Urology*. 2022;14.
IMPACT FACTOR (2022): 2,000
115. Ferro M, Marchioni M, Lucarelli G, Vartolomei MD, Soria F, Terracciano D, Mistretta FA, Luzzago S, Buonerba C, Cantiello F, Mari A, Minervini A, Veccia A, Antonelli A, Musi G, Hurle R, Busetto GM, DEL GIUDICE F, Chung BI, Berardinelli F, Perdonà S, Del Prete P, Mirone V, Borghesi M, Porreca A, Bove P, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Ditunno P, Russo GI, Muto M, Damiano R, Manfredi M, Porpiglia F, de Cobelli O, Schips L. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. *Minerva Urology and Nephrology*. 2022;73(6):796–802.
IMPACT FACTOR (2021): 5,214
116. Ferro M, Tătaru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, Damiano R, Hurle R, Contieri R, Busetto GM, Carrieri G, Cormio L, DEL GIUDICE F, Sciarra A, Perdonà S, Borghesi M, Terrone C, La Civita E, Bove P, Autorino R, Muto M, Crisan N, Marchioni M, Schips L, Soria F, Terracciano D, Papalia R, Crocetto F, Barone B, Russo GI, Luzzago S, Ludovico GM, Vartolomei MD, Mistretta FA, Mirone V, de Cobelli O. Modified Glasgow

Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. *Diagnostics* . 2022;12(3).

IMPACT FACTOR (2022): 3,600

117. Ferro M, Terracciano D, Musi G, De Cobelli O, Vartolomei MD, Damiano R, Cantiello F, Buonerba C, Morelli M, Mistretta FA, Luzzago S, Perdonà S, Del Prete P, **DEL GIUDICE F**, Busetto GM, Porreca A, Autorino R, Manfredi M, Porpiglia F, Muto M, Loizzo D, Ditunno P, Battaglia M, Lucarelli G. Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. *Urologia Internationalis*. 2022;106(1):75–82.

IMPACT FACTOR (2022): 1,600

118. Frisenda M, Signore S, Delicato G, Martinelli AG, Cantiani A, Colafelice M, Tufano A, **DEL GIUDICE F**, Eisenberg ML, Sciarra A, Canale V. Influence of COVID-19 pandemic on timing and outcomes of treatment for acute testicular torsion in adults: a single institution experience. *The Canadian journal of urology*. 2022;29(2):11095–11100.

IMPACT FACTOR (2022): 1,500

119. Glover F, Eisenberg ML, Belladelli F, **DEL GIUDICE F**, Chen T, Mulloy E, Caudle WM. The association between organophosphate insecticides and blood pressure dysregulation: NHANES 2013–2014. *Environmental Health: A Global Access Science Source* . 2022 Aug 8;21(1):74

IMPACT FACTOR (2022): 6,000

120. Glover F, Steenland K, Eisenberg ML, Belladelli F, Mulloy E, **DEL GIUDICE F**, Caudle WM. The association between organophosphate insecticides, blood pressure dysregulation, and metabolic syndrome among U.S. Adults: NHANES 2015-2016. *Hygiene and Environmental Health Advances*. 2022 Aug 8;21(1):74.

IMPACT FACTOR (2022): 6,000

121. Glover FE, Caudle WM, **DEL GIUDICE F**, Belladelli F, Mulloy E, Lawal E, Eisenberg ML. The association between caffeine intake and testosterone: NHANES 2013–2014. *Nutrition Journal* . 2022 Apr;45(4):787–796

IMPACT FACTOR (2022): 5,400

122. Glover FE, **DEL GIUDICE F**, Belladelli F, Ryan PB, Chen T, Eisenberg ML, Caudle WM. Correction to: The association between 2,4-D and serum testosterone levels: NHANES 2013–2014. *Journal of Endocrinological Investigation*. 2022;45(4):909.

IMPACT FACTOR (2022): 5,400

123. Glover FE, **DEL GIUDICE F**, Belladelli F, Ryan PB, Chen T, Eisenberg ML, Caudle WM. The association between 2,4-D and serum testosterone levels: NHANES 2013–2014. *Journal of Endocrinological Investigation*. 2022;45(4):787–796.

IMPACT FACTOR (2022): 5,400

124. Krajewski W, Aumatell J, Subiela JD, Nowak Ł, Tukiendorf A, Moschini M, Basile G, Poletajew S, Małkiewicz B, **DEL GIUDICE F**, Maggi M, Chung BI, Cimadamore A, Galosi AB, Fave RFD, D'Andrea D, Shariat SF, Hornak J, Babjuk M, Chorbińska J, Teoh JYC, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Panunzio A, Alvarez-Maestro M, Simone G, Mastroianni R, Łaskiewicz J, Lonati C, Zamboni S, Simeone C, Niedziela Ł, Candela L, Macek P, Contieri R, Hidalgo BG, Rivas JG, Sosnowski R, Mori K, Mir C, Soria F, González-Padilla DA, Faba ÒR, Palou J, Ploussard G, Rajwa P, Hałóń A, Laukhtina E, Pradere B, Tully K, Burgos FJ, Cidre MÁJ, Szydelko T. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. *Urologic Oncology: Seminars and Original Investigations*. 2022;40(11):491.e11-491.e19.
IMPACT FACTOR (2022): 2,700
125. Loizzo D, Pandolfo SD, **DEL GIUDICE F**, Cerrato C, Chung BI, Wu Z, Imbimbo C, Ditunno P, Derweesh I, Autorino R. Ureteroscopy and tailored treatment of upper tract urothelial cancer: recent advances and unmet needs. *BJU International*. 2022;130(1):35–37.
IMPACT FACTOR (2022): 4,500
126. Messina E, Pisciotto ML, Pecoraro M, Borrelli A, **DEL GIUDICE F**, Panebianco V. The use of MRI in urothelial carcinoma. *Current Opinion in Urology*. 2022;32(5):536–544.
IMPACT FACTOR (2022): 2,500
127. Morgantini LA, Del Pino M, Bharadwaj A, Alzein A, Ganesh A, Egan E, **DEL GIUDICE F**, Crivellaro S. Single-port Versus Multi-port Robotic-assisted Procedures From the Patient's Perspective: A Retrospective Cohort Study. *Urology Practice*. 2022;9(6):575–579.
IMPACT FACTOR (2022): N/A
128. Nowak Ł, Krajewski W, Łaskiewicz J, Małkiewicz B, Chorbińska J, **DEL GIUDICE F**, Mori K, Moschini M, Kaliszewski K, Rajwa P, Laukhtina E, Shariat SF, Szydelko T. The Impact of Surgical Waiting Time on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: A Systematic Review. *Journal of Clinical Medicine*. 2022;11(14).
IMPACT FACTOR (2022): 3,900
129. Pandolfo SD, Aveta A, Loizzo D, Crocerossa F, La Rocca R, **DEL GIUDICE F**, Chung BI, Wu Z, Lucarelli G, Mirone V, Imbimbo C, Autorino R. Quality of Web-Based Patient Information on Robotic Radical Cystectomy Remains Poor: A Standardized Assessment. *Urology Practice*. 2022;9(5):498–503.
IMPACT FACTOR (2022): N/A
130. Panebianco V, Pecoraro M, **DEL GIUDICE F**, Takeuchi M, Muglia VF, Messina E, Cipollari S, Giannarini G, Catalano C, Narumi Y. VI-RADS for Bladder Cancer: Current Applications and Future Developments. *Journal of Magnetic Resonance Imaging*. 2022;55(1):23–36.
IMPACT FACTOR (2022): 2,200

131. Pecoraro M, **DEL GIUDICE F**, Magliocca F, Simone G, Flammia S, Leonardo C, Messina E, De Berardinis E, Cortesi E, Panebianco V. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. *Abdominal Radiology*. 2022;47(2):763–770.
IMPACT FACTOR (2022): 2,400
132. Romano L, Pellegrino R, Sciorio C, Barone B, Gravina AG, Santonastaso A, Mucherino C, Astretto S, Napolitano L, Aveta A, Pandolfo SD, Loizzo D, **DEL GIUDICE F**, Ferro M, Imbimbo C, Romano M, Crocetto F. Erectile and sexual dysfunction in male and female patients with celiac disease: A cross-sectional observational study. *Andrology*. 2022;10(5):910–918.
IMPACT FACTOR (2022): 4,600
133. Salciccia S, De Marco F, Sciarra A, Moriconi M, Alfaroni A, Polese M, Maggi M, **DEL GIUDICE F**, Gentilucci A, De Berardinis E, Ricciuti GP. Allium stent as a curative treatment for benign ureteral strictures: Preliminary experience, surgical technique, and functional results. *Frontiers in Urology*. 2022;2.
IMPACT FACTOR (2022): N/A
134. Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, **DEL GIUDICE F**, Carbone A, Pastore A, Chung BI, Eisenberg ML, Autorino R, Crivellaro S, Forte F, Sciarra A, Mariotti G, Gentilucci A. Comparative Prospective and Longitudinal Analysis on the Platelet-to-Lymphocyte, Neutrophil-to-Lymphocyte, and Albumin-to-Globulin Ratio in Patients with Non-Metastatic and Metastatic Prostate Cancer. *Current Oncology*. 2022;29(12):9474–9500.
IMPACT FACTOR (2022): 2,600
135. Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, **DEL GIUDICE F**, Sciarra A, Mariotti G, Gentilucci A. Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review. *International Journal of Molecular Sciences* . 2022;23(19).
IMPACT FACTOR (2022): 5,600
136. Salciccia S, Sciarra A, Moriconi M, Maggi M, Viscuso P, Rosati D, Frisenda M, Di Pierro GB, Canale V, Bevilacqua G, Nesi G, **DEL GIUDICE F**, Gentilucci A, Cattarino S, Mariotti G. How to predict outcomes from a biofeedback and pelvic floor muscle electric stimulation program in patients with urinary incontinence after radical prostatectomy. *Journal of Clinical Medicine* . 2022;11(1).
IMPACT FACTOR (2021): 4,964
137. Salciccia S, Viscuso P, Bevilacqua G, Tufano A, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Gentilucci A, Lourdes Lia F, Ivan DG, Rosati D, **DEL GIUDICE F**, Sciarra A, Mariotti G. Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy. *Advances in Urology*. 2022;2022:8736249.
IMPACT FACTOR (2022): 1,400

138. Sciarra A, Fiori C, **DEL GIUDICE F**, Di Pierro G, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G, Salciccia S. DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives. *Minerva Urology and Nephrology*. 2022;74(6):649–652.
IMPACT FACTOR (2022): 4,900
139. Stangl-Kremser J, Lambertini L, Di Maida F, Martinez-Fundichely A, Ferro M, Pradere B, Soria F, Albisinni S, Wu Z, **DEL GIUDICE F**, Cacciamani GE, Valerio M, Briganti A, Rouprêt M, Shariat SF, Lee C, Minervini A, Moschini M, Mari A. Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. *European Urology Focus*. 2022;8(6):1622–1626.
IMPACT FACTOR (2022): 5,400
140. Tafuri A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Panunzio A, Trovato F, Catellani M, Janello LMI, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, De Cobelli O, Maiorino F, Bove P, Crocerossa F, Cantiello F, D'Andrea D, Di Cosmo F, Porpiglia F, Ditunno P, Montanari E, Soria F, Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, **DEL GIUDICE F**, Sciarra A, Galosi A, Moschini M, Shariat SF, Di Nicola M, Minervini A, Ferro M, Cerruto MA, Schips L, Pagliarulo V, Antonelli A. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). *World Journal of Urology*. 2022;40(11):2771–2779.
IMPACT FACTOR (2022): 3,400
141. Vartolomei L, Cotruș A, Stanciu C, Delcea C, Tozzi M, Lievore E, Crocetto F, **DEL GIUDICE F**, Lucarelli G, Muto M, Ferro M. Quality of Life and Psychological Distress among Patients with Small Renal Masses. *Journal of Clinical Medicine* . 2022;11(14).
IMPACT FACTOR (2022): 3,900
142. Asero V, Krajewski W, Pradere B, D'Andrea D, Moschini M, Soria F, Gallioli A, Basran S, Chung BI, **DEL GIUDICE F**. Comment on: “Do perioperative blood transfusions impact oncological outcomes of robot-assisted radical cystectomy with intracorporeal urinary diversion? Results from a large multi-institutional registry.” *Minerva Urology and Nephrology*. 2023;75(2):248–250.
IMPACT FACTOR (2023): 4,900
143. Asero V, Scornajenghi CM, Carino D, Pandolfo SD, Krajewski W, Gallioli A, Basran S, Tresh A, Chung BI, **DEL GIUDICE F**. Comment on: “Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.” *Minerva Urology and Nephrology*. 2023;75(5):649–651.
IMPACT FACTOR (2023): 4,900
144. Asero V, Scornajenghi CM, Krajewski W, Szydełko T, Malkiewicz B, Nowak Ł, Gallioli A, Basran S, Chung BI, **DEL GIUDICE F**. Comment on: “Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation

as an adjuvant therapy in upper urothelial carcinoma.” *Minerva Urology and Nephrology*. 2023;75(3):401–403.

IMPACT FACTOR (2023): 4,900

145. Aveta A, Cilio S, Contieri R, Spena G, Napolitano L, Manfredi C, Franco A, Crocerossa F, Cerrato C, Ferro M, **DEL GIUDICE F**, Verze P, Lasorsa F, Salonia A, Nair R, Walz J, Lucarelli G, Pandolfo SD. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. *International Journal of Molecular Sciences* . 2023;24(13).

IMPACT FACTOR (2023): 4,900

146. Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A, Di Maida F, Pradere B, Mertens LS, Longoni M, Krajewski W, **DEL GIUDICE F**, D’Andrea D, Laukhtina E, Shariat SF, Minervini A, Moschini M, Mari A. Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence. *Cancers*. 2023;15(11).

IMPACT FACTOR (2023): 4,500

147. Barone B, Finati M, Cinelli F, Fanelli A, **DEL GIUDICE F**, De Berardinis E, Sciarra A, Russo G, Mancini V, D’Altilia N, Ferro M, Porreca A, Chung BI, Basran S, Bettocchi C, Cormio L, Imbimbo C, Carrieri G, Crocetto F, Busetto GM. Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence. *Journal of Personalized Medicine*. 2023;13(3).

IMPACT FACTOR (2023): 3,000

148. Barone B, Mirto BF, Falcone A, **DEL GIUDICE F**, Aveta A, Napolitano L, Del Biondo D, Ferro M, Busetto GM, Manfredi C, Terracciano D, Gambardella R, Pandolfo SD, Trama F, De Luca C, Martino R, Capone F, Giampaglia G, Sicignano E, Tataru OS, Lucarelli G, Crocetto F. The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial. *Journal of Clinical Medicine* . 2023;12(8).

IMPACT FACTOR (2023): 3,000

149. Basile G, de Angelis M, Leni R, Re C, Longoni M, Mari A, Soria F, Pradere B, **DEL GIUDICE F**, Laukhtina E, D’Andrea D, Mori K, Krajewski W, Albisinni S, Gallioli A, Breda A, Esperto F, Briganti A, Montorsi F, Moschini M, Carando R. Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review. *Minerva Urology and Nephrology*. 2023;75(3):278–288.

IMPACT FACTOR (2023): 4,900

150. Belladelli F, **DEL GIUDICE F**, Glover F, Mulloy E, Muncey W, Basran S, Fallara G, Pozzi E, Montorsi F, Salonia A, Eisenberg ML. Worldwide Temporal Trends in Penile Length: A Systematic Review and Meta-Analysis. *World Journal of Men’s Health*. 2023 Oct;41(4):848–860.

IMPACT FACTOR (2023): 4,000

151. Belladelli F, Li S, Zhang CA, Muncey W, **DEL GIUDICE F**, Glover F, Seranio N, Basran S, Fallara G, Montorsi F, Salonia A, Eisenberg ML. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events. *Journal of Sexual Medicine*. 2023;20(12):1399–1406.

IMPACT FACTOR (2023): 3,300

152. Borrelli A, Pecoraro M, **DEL GIUDICE F**, Cristofani L, Messina E, Dehghanpour A, Landini N, Roberto M, Perotti S, Muscaritoli M, Santini D, Catalano C, Panebianco V. Standardization of Body Composition Status in Patients with Advanced Urothelial Tumors: The Role of a CT-Based AI-Powered Software for the Assessment of Sarcopenia and Patient Outcome Correlation. *Cancers*. 2023 May 29;15(11)

IMPACT FACTOR (2023): 4,500

153. Busetto GM, Finati M, Chirico M, Cinelli F, D'Altillia N, Falagario UG, Sanguedolce F, **DEL GIUDICE F**, De Berardinis E, Ferro M, Crocetto F, Porreca A, Di Gianfrancesco L, Calo' B, Mancini V, Bettocchi C, Carrieri G, Cormio L. Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle? *World Journal of Urology*. 2023;41(5):1329–1335.

IMPACT FACTOR (2023): 2,800

154. Carrión DM, Pradere B, Soria F, **DEL GIUDICE F**, Moschini M. Editorial commentary on: "Reduced vs full-dose BCG therapy in bladder cancer: A systematic review and meta-analysis." *Actas Urologicas Espanolas*. 2023;47(1):1–3.

IMPACT FACTOR (2023): 1,200

155. Chorbińska J, Krajewski W, Nowak Ł, Małkiewicz B, **DEL GIUDICE F**, Szydełko T. Urinary Microbiome in Bladder Diseases—Review. *Biomedicines* . 2023;11(10).

IMPACT FACTOR (2023): 3,900

156. Contieri R, Hurle R, Paciotti M, Casale P, Saita A, Porpiglia F, Fiori C, Barone B, Crocetto F, Lucarelli G, Busetto GM, **DEL GIUDICE F**, Maggi M, Cantiello F, Damiano R, Borghesi M, Bove P, Bertolo R, Papalia R, Mari A, Luzzago S, Mistretta FA, Soria F, Gontero P, Marchioni M, la Civita E, Terracciano D, Russo GI, Schips L, Perdoni S, Mirone V, Tataru OS, Musi G, Vartolomei MD, Autorino R, Montanari E, de Cobelli O, Ferro M. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. *Minerva Urology and Nephrology*. 2023;75(2):180–187.

IMPACT FACTOR (2023): 4,900

157. Crocetto F, Balsamo R, Amicuzi U, De Luca L, Falcone A, Mirto BF, Giampaglia G, Ferretti G, Capone F, Machiella F, Varriale D, Sicignano E, Pagano G, Lombardi A, Lucarelli G, Lasorsa F, Busetto GM, **DEL GIUDICE F**, Ferro M, Imbimbo C, Barone B. Novel Key Ingredients in Urinary Tract Health—The Role of D-mannose, Chondroitin Sulphate, Hyaluronic Acid, and N-acetylcysteine in Urinary Tract Infections (Uroial PLUS®). *Nutrients*. 2023 Aug 14;15(16).

IMPACT FACTOR (2023): 4,800

158. Crocetto F, Ferro M, Buonerba C, Bardi L, Dolce P, Scafuri L, Mirto BF, Verde A, Sciarra A, Barone B, Calogero A, Sagnelli C, Busetto GM, **DEL GIUDICE F**, Cilio S, Sonpavde G, Di

Trolio R, Della Ratta GL, Barbato G, Di Lorenzo G. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone. *Critical Reviews in Oncology Hematology*. 2023 Aug;188:104059.

IMPACT FACTOR (2023): 5,500

159. Crocetto F, Imbimbo C, Barone B, Turchino D, Bracale UM, Peluso A, Panagrosso M, Falcone A, Mirto BF, De Luca L, Sicignano E, **DEL GIUDICE F**, Busetto GM, Lucarelli G, Giampaglia G, Manfredi C, Ferro M, Tarantino G. Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms? *Basic and Clinical Andrology* . 2023 Dec 19;33(1):38

IMPACT FACTOR (2023): 2,400

160. De Angelis M, Basile G, Scornajenghi CM, Asero V, **DEL GIUDICE F**, Moschini M. Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer. *Current Opinion in Urology*. 2023;33(5):354–359.

IMPACT FACTOR (2023): 2,100

161. **DEL GIUDICE F**, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, Viscuso P, Salciccia S, Sciarra A, D'Andrea D, Pradere B, Moschini M, Mari A, Albisinni S, Krajewski W, Szydelko T, Małkiewicz B, Nowak Ł, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Soria F, Mori K, Tully KH, Pichler R, Ferro M, Tataru OS, Autorino R, Crivellaro S, Crocetto F, Busetto GM, Basran S, Eisenberg ML, Chung BI, De Berardinis E. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. *Cancers* . 2023;15(7).

IMPACT FACTOR (2023): 4,500

162. **DEL GIUDICE F**, Belladelli F, Glover F, Basran S, Li S, Mulloy E, Pradere B, Soria F, Krajewski W, Nair R, Muncey W, Seranio N, Eisenberg ML. 5-alpha reductase inhibitors (5-ARI) with or without alpha-blockers (α -B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data. *World Journal of Urology*. 2023;41(10):2783–2791.

IMPACT FACTOR (2023): 2,800

163. **DEL GIUDICE F**, D'Andrea D, Pradere B, Berndt F, Pallauf M, Flammia RS, Philipp D, Moschini M, Mari A, Albisinni S, Krajewski W, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Gontero P, Shariat SF, Chung BI, Soria F. Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators. *BJU International*. 2023;131(6):712–719.

IMPACT FACTOR (2023): 3,700

164. **DEL GIUDICE F**, Huang J, Li S, Sorensen S, Enemchukwu E, Maggi M, Salciccia S, Ferro M, Crocetto F, Pandolfo SD, Autorino R, Krajewski W, Crivellaro S, Cacciamani GE, Bologna E, Asero V, Scornajenghi C, Moschini M, D'Andrea D, Brown DR, Chung BI. Contemporary

trends in the surgical management of urinary incontinence after radical prostatectomy in the United States. *Prostate Cancer and Prostatic Diseases*. 2023;26(2):367–373.

IMPACT FACTOR (2023): 5,100

165. DEL GIUDICE F, Kim W, Li S, de Berardinis E, Sciarra A, Salciccia S, Ferro M, Autorino R, Pandolfo SD, Crocetto F, Galfano A, Dell'Oglio P, Cacciamani GE, Pradere B, Laukhtina E, D'Andrea D, Belladelli F, Krajewski W, Mari A, Minervini A, Gallioli A, Amparore D, Checcucci E, Fiori C, Porpiglia F, Morgantini L, Crivellaro S, Chung BI. Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and perioperative outcomes. *Minerva Urology and Nephrology*. 2023;75(1):73–84.

IMPACT FACTOR (2023): 4,900

166. Di Pierro GB, Bucca B, Sciarra A, DEL GIUDICE F, Frisenda M, Salciccia S. Unexpected discovery of surgical gauze during a robotic radical prostatectomy identified as a capturing lymph node on magnetic resonance. *Urology Case Reports*. 2023 Jan;46:102301.

IMPACT FACTOR (2023): N/A

167. Di Pierro GB, Salciccia S, Frisenda M, Tufano A, Sciarra A, Scarrone E, DEL GIUDICE F, Asero V, Bevilacqua G, Moriconi M, Carbone A, Pastore A, Signore S, Bove P, Forte F, Emiliozzi P, Tubaro A, De Nunzio C, Canale V. Comparison of Four Validated Nomograms (Memorial Sloan Kettering Cancer Center, Briganti 2012, 2017, and 2019) Predicting Lymph Node Invasion in Patients with High-Risk Prostate Cancer Candidates for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Clinical Experience and Review of the Literature. *Cancers* . 2023 Mar 9;15(6).

IMPACT FACTOR (2023): 4,500

168. Falagario UG, Lantz A, Jambor I, Busetto GM, Bettocchi C, Finati M, Ricapito A, Luzzago S, Ferro M, Musi G, Totaro A, Racioppi M, Carbonara U, Checcucci E, Manfredi M, D'Aietti D, Porcaro AB, Nordström T, Björnebo L, Oderda M, Soria F, Taimen P, Aronen HJ, Perez IM, Ettala O, Marchioni M, Simone G, Ferriero M, Brassetti A, Napolitano L, Carmignani L, Signorini C, Conti A, Ludovico G, Scarcia M, Trombetta C, Claps F, Traunero F, Montanari E, Boeri L, Maggi M, DEL GIUDICE F, Bove P, Forte V, Ficarra V, Rossanese M, Mucciardi G, Pagliarulo V, Tafuri A, Mirone V, Schips L, Antonelli A, Gontero P, Cormio L, Sciarra A, Porpiglia F, Bassi PF, Ditunno P, Boström PJ, Messina E, Panebianco V, De Cobelli O, Carrieri G. Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. *World Journal of Urology*. 2023;41(11):2967–2974.

IMPACT FACTOR (2023): 2,800

169. Ferro M, Crocetto F, Barone B, DEL GIUDICE F, Maggi M, Lucarelli G, Busetto GM, Autorino R, Marchioni M, Cantiello F, Crocerossa F, Luzzago S, Piccinelli M, Mistretta FA, Tozzi M, Schips L, Falagario UG, Veccia A, Vartolomei MD, Musi G, de Cobelli O, Montanari E, Tătaru OS. Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. *Therapeutic Advances in Urology* . 2023;15.

IMPACT FACTOR (2023): 2,600

170. Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, Sonpavde G, Musi G, Antonelli A, Veccia A, Terracciano D, Busetto GM, **DEL GIUDICE F**, Marchioni M, Schips L, Porpiglia F, Fiori C, Carrieri G, Lasorsa F, Verde A, Scafuri L, Buonerba C, Di Lorenzo G. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *Clinical Genitourinary Cancer*. 2023;21(5):574–583.
IMPACT FACTOR (2023): 2,300
171. Ferro M, Falagario UG, Barone B, Maggi M, Crocetto F, Busetto GM, **DEL GIUDICE F**, Terracciano D, Lucarelli G, Lasorsa F, Catellani M, Brescia A, Mistretta FA, Luzzago S, Piccinelli ML, Vartolomei MD, Jereczek-Fossa BA, Musi G, Montanari E, Cobelli OD, Tataru OS. Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement. *Diagnostics* . 2023;13(13).
IMPACT FACTOR (2023): 3,000
172. Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, **DEL GIUDICE F**, Barone B, Crocetto F, Lasorsa F, Antonelli A, Schips L, Autorino R, Busetto GM, Terracciano D, Lucarelli G, Tataru OS. Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. *International Journal of Molecular Sciences* . 2023;24(5).
IMPACT FACTOR (2023): 4,900
173. Ferro M, Rocco B, Maggi M, Lucarelli G, Falagario UG, **DEL GIUDICE F**, Crocetto F, Barone B, La Civita E, Lasorsa F, Brescia A, Catellani M, Busetto GM, Tataru OS, Terracciano D. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification. *Expert Review of Molecular Diagnostics*. 2023;23(12):1061–1070.
IMPACT FACTOR (2023): 3,900
174. Flammia RS, Tufano A, Chierigo F, Würnschimmel C, Hoeh B, Sorce G, Tian Z, Anceschi U, Leonardo C, **DEL GIUDICE F**, Terrone C, Giordano A, Morrione A, Saad F, Shariat SF, Briganti A, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer. *Journal of Clinical Medicine* . 2023;12(5).
IMPACT FACTOR (2023): 3,000
175. Franco A, Ditunno F, Feng C, Manfredi C, Sturgis MR, Farooqi M, **DEL GIUDICE F**, Coogan C, Ferro M, Zhang C, Wu Z, Yang B, Wang L, Autorino R. Minimally Invasive Radical Nephroureterectomy: 5-Year Update of Techniques and Outcomes. *Cancers* . 2023;15(18).
IMPACT FACTOR (2023): 4,500
176. Gallioli A, Baboudjian M, Diana P, Moschini M, Xylinas E, **DEL GIUDICE F**, Laukhtina E, Soria F, Mari A, Subiela JD, Rouy M, Territo A, Basile G, Palou J, Pradere B, Breda A. Perioperative and oncological outcomes of distal ureter management during nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. *Minerva Urology and Nephrology*. 2023;75(6):672–682.
IMPACT FACTOR (2023): 4,900
177. Glover F, Barr D, Eatman J, Muncey W, **DEL GIUDICE F**, Belladelli F, Seranio N, Eisenberg

ML. Evaluation of glyphosate exposure on testosterone among U.S. adult men. Human and Ecological Risk Assessment. 2023;29(5–6):902–915. +

IMPACT FACTOR (2023): 3,000

178. Glover F, Jean-Baptiste O, DEL GIUDICE F, Belladelli F, Seranio N, Muncey W, Eisenberg ML. The association between glyphosate exposure and metabolic syndrome among U.S. adults. Human and Ecological Risk Assessment. 2023;29(9–10):1212–1225.

IMPACT FACTOR (2023): 3,000

179. Lee S, Yoo KH, Kim TS, Cho HJ, Kim W, Oh JK, Li S, Kim SY, Wei W, Huang J, van Uem S, DEL GIUDICE F, Lindars DP, Sathe AR, Chung BI. Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US-based insurance claims database. Prostate. 2023;83(7):722–728.

IMPACT FACTOR (2023): 2,600

180. Leonardo C, Flammia RS, Lucciola S, Proietti F, Pecoraro M, Bucca B, Licari LC, Borrelli A, Bologna E, Landini N, Del Monte M, Chung BI, Catalano C, Magliocca FM, De Berardinis E, DEL GIUDICE F, Panebianco V. Performance of Node-RADS Scoring System for a Standardized Assessment of Regional Lymph Nodes in Bladder Cancer Patients. Cancers . 2023;15(3).

IMPACT FACTOR (2023): 4,500

181. Lonati C, Soria F, Pradere B, D’Andrea D, Laukhtina E, Mertens LS, Albisinni S, Krajewski W, Afferi L, DEL GIUDICE F, Gallioli A, Moschini M. Comment on: “Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.” Minerva Urology and Nephrology. 2023;75(3):407–409.

IMPACT FACTOR (2023): 4,900

182. Lucciola S, Pisciotto ML, Frisenda M, Magliocca F, Gentilucci A, DEL GIUDICE F, Canale V, Scarrone E, Busetto GM, Carrieri G, Cormio L, Carbone A, Pastore A, De Nunzio C, Tubaro A, Leonardo C, Franco G, Di Pierro GB, Salciccia S, Sciarra A, Panebianco V. Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms. Prostate Cancer and Prostatic Diseases. 2023;26(2):379–387.

IMPACT FACTOR (2023): 5,100

183. Messina E, Pecoraro M, Pisciotto ML, DEL GIUDICE F, Lucciola S, Bicchetti M, Laschena L, Roberto M, De Berardinis E, Franco G, Panebianco V. Seeing is Believing: State of the Art Imaging of Bladder Cancer. Seminars in Radiation Oncology. 2023;33(1):12–20.

IMPACT FACTOR (2023): 2,600

184. Mulloy E, Li S, Belladelli F, DEL GIUDICE F, Glover F, Eisenberg ML. Association between priapism and HIV disease and treatment. Journal of Sexual Medicine. 2023;20(4):536–541.

IMPACT FACTOR (2023): 3,300

185. Mulloy E, Li S, Belladelli F, **DEL GIUDICE F**, Glover F, Eisenberg ML. The Risk of Cardiovascular and Cerebrovascular Disease in Men with a History of Priapism. *Journal of Urology*. 2023;209(1):253–260.
IMPACT FACTOR (2023): 5,900
186. Pallauf M, D’Andrea D, König F, Laukhtina E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian SA, Potretzke AM, Mari A, Roumiguié M, Antonelli A, Bianchi A, Khene ZE, Sfakianos JP, Jamil M, Boormans JL, Raman JD, Grossmann NC, Breda A, Heidenreich A, **DEL GIUDICE F**, Singla N, Shariat SF, Pradere B. Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study. *Journal of Urology*. 2023;209(3):515–524.
IMPACT FACTOR (2023): 5,900
187. Pandolfo SD, Carbonara U, Beksac AT, Derweesh I, Celia A, Schiavina R, Elbich J, Basile G, Hampton LJ, Cerrato C, Costa G, Bianchi L, Lucarelli G, Mirone V, Imbimbo C, Kim FJ, **DEL GIUDICE F**, Capitanio U, Kaouk J, Autorino R. Microwave versus cryoablation and radiofrequency ablation for small renal mass: a multicenter comparative analysis. *Minerva Urology and Nephrology*. 2023;75(1):66–72.
IMPACT FACTOR (2023): 4,900
188. Pandolfo SD, Cerrato C, Wu Z, Franco A, **DEL GIUDICE F**, Sciarra A, Verze P, Lucarelli G, Imbimbo C, Perdonà S, Cherullo EE, Porpiglia F, Derweesh IH, Autorino R. A systematic review of robot-assisted partial nephrectomy outcomes for advanced indications: Large tumors (cT2-T3), solitary kidney, completely endophytic, hilar, recurrent, and multiple renal tumors. *Asian Journal of Urology*. 2023;10(4):390–406.
IMPACT FACTOR (2023): 3,000
189. Pandolfo SD, Crauso F, Aveta A, Cilio S, Barone B, Napolitano L, Scarpato A, Mirto BF, Serino F, **DEL GIUDICE F**, Chung BI, Crocerossa F, Di Zazzo E, Trama F, Vaglio R, Wu Z, Verze P, Imbimbo C, Crocetto F. A Novel Low-Cost Uroflowmetry for Patient Telemonitoring. *International Journal of Environmental Research and Public Health*. 2023;20(4).
IMPACT FACTOR (2023): 4,614
190. Pandolfo SD, **DEL GIUDICE F**, Chung BI, Manfredi C, De Sio M, Damiano R, Cherullo EE, De Nunzio C, Cacciamani GE, Cindolo L, Porpiglia F, Mirone V, Imbimbo C, Autorino R, Crocerossa F. Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases. *Prostate Cancer and Prostatic Diseases*. 2023;26(3):495–510.
IMPACT FACTOR (2023): 5,100
191. Piszczek R, Krajewski W, Subiela JD, **DEL GIUDICE F**, Nowak Ł, Chorbińska J, Moschini M, Masson-Lecomte A, Bebane S, Cimadamore A, Grobet-Jeandin E, Rouprêt M, D’Andrea D, Mastroianni R, Gutierrez Hidalgo B, Gomez Rivas J, Mori K, Soria F, Laukhtina E, Mari A, Albisinni S, Gallioli A, Mertens LS, Pichler R, Marcq G, Łaszkiewicz J, Hałoń A, Carrion DM, Akand M, Pradere B, Shariat SF, Palou J, Babjuk M, Burgos Revilla J, Małkiewicz B, Szydełko

T. Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy. *Minerva Urology and Nephrology*. 2023;75(5):591–599.

IMPACT FACTOR (2023): 4,900

192. Salciccia S, Maggi M, Frisenda M, Finistauri Guacci L, Hoxha S, Licari LC, Viscuso P, Gentilucci A, **DEL GIUDICE F**, de Berardinis E, Cattarino S, Mariotti G, Tufano A, de Dominicis M, Ricciuti GP, Sciarra A, Penniston KL, Moriconi M. Translation and validation of the Italian version of the Wisconsin Stone Quality of Life Questionnaire (I-WISQOL) for assessing quality of life in patients with urolithiasis. *Minerva Urology and Nephrology*. 2023;75(4):501–507.

IMPACT FACTOR (2023): 4,900

193. Sciarra A, Frisenda M, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G, **DEL GIUDICE F**, Di Pierro GB, Viscuso P, Casale P, Chung BI, Autorino R, Crivellaro S, Salciccia S. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients. *International Journal of Molecular Sciences* . 2023;24(1).

IMPACT FACTOR (2023): 4,900

194. Scornajenghi CM, Asero V, Bologna E, Basile G, De Angelis M, Moschini M, **DEL GIUDICE F**. Organ-sparing treatment for T1 and T2 penile cancer: An updated literature review. *Current Opinion in Urology*. 2023;33(5):383–389.

IMPACT FACTOR (2023): 2,100

195. Tataru OS, Marchioni M, Crocetto F, Barone B, Lucarelli G, **DEL GIUDICE F**, Busetto GM, Veccia A, Lo Giudice A, Russo GI, Luzzago S, Piccinelli ML, Vartolomei MD, Musi G, Ferro M. Molecular Imaging Diagnosis of Renal Cancer Using 99mTc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques. *Diagnostics* . 2023;13(4).

IMPACT FACTOR (2023): 3,000

196. von Deimling M, Mertens LS, van Rhijn BWG, Lotan Y, Spiess PE, Daneshmand S, Black PC, Pallauf M, D'Andrea D, Moschini M, Soria F, **DEL GIUDICE F**, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh JYC, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz PI, Babjuk M, Gontero P, Xylinas E, Rink M, Shariat SF, Pradere B. Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer. *European Urology Open Science*. 2023;51:39–46.

IMPACT FACTOR (2023): 3,200

197. Belladelli F, Li S, Zhang CA, **DEL GIUDICE F**, Basran S, Muncey W, Glover F, Seranio N, Fallara G, Montorsi F, Salonia A, Eisenberg ML. The Association Between Insomnia, Insomnia Medications, and Erectile Dysfunction. *European Urology Focus*. 2024;10(1):139–145.

IMPACT FACTOR (2023): 4,800

198. Buonerba C, Calabrese AN, Imperioso G, Piscosquito A, Verde A, Vaia A, Scafuri L, Crocetto F, Leopardo D, Rocco B, **DEL GIUDICE F**, Tufano A, Casale B, Cappuccio F, Chiancone F,

Di Trolio R, Di Lorenzo G. Instant Messaging in Cancer Care. *Oncology (Switzerland)*. 2024;102(8):659–662.

IMPACT FACTOR (2023): 2,500

199. Busetto GM, Checchia A, Recchia M, Tocci E, Falagario UG, Annunziata G, Annese P, d'Altilla N, Mancini V, Ferro M, Crocetto F, Tataru OS, Di Gianfrancesco L, Porreca A, **DEL GIUDICE F**, De Berardinis E, Bettocchi C, Cormio L, Carrieri G. Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea? *Asian Journal of Andrology*. 2024;26(2):135–143.

IMPACT FACTOR (2023): 3,000

200. Contieri R, Pichler R, **DEL GIUDICE F**, Marcq G, Gallioli A, Albisinni S, Soria F, d'Andrea D, Krajewski W, Carrion DM, Mari A, van Rhijn BWG, Moschini M, Pradere B, Mertens LS. Variation in Follow-Up after Radical Cystectomy for Bladder Cancer—An Inventory Roundtable and Literature Review. *Journal of Clinical Medicine*. 2024;13(9).

IMPACT FACTOR (2023): 3,000

201. Crocetto F, Falcone A, Mirto BF, Sicignano E, Pagano G, Dinacci F, Varriale D, Machiella F, Giampaglia G, Calogero A, Varlese F, Balsamo R, Trama F, Sciarra A, **DEL GIUDICE F**, Busetto GM, Ferro M, Lucarelli G, Lasorsa F, Imbimbo C, Barone B. Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring. *International Journal of Molecular Sciences*. 2024;25(7).

IMPACT FACTOR (2023): 4,900

202. **DEL GIUDICE F**, Tresh A, Li S, Basran S, Prendiville SG, Belladelli F, de Berardinis E, Asero V, Scornajenghi CM, Carino D, Ferro M, Rocco B, Maria Busetto G, Falagario U, Autorino R, Crocetto F, Barone B, Pradere B, Krajewski W, Nowak Ł, Szydełko T, Moschini M, Mari A, Crivellaro S, Porpiglia F, Fiori C, Amparore D, Pichler R, Rane A, Challacombe B, Nair R, Chung BI. The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs. *Minerva Urology and Nephrology*. 2024;76(3):320–330.

IMPACT FACTOR (2023): 4,900

203. Di Pierro GB, Di Lascio G, Lemma A, Grande P, Frisenda M, **DEL GIUDICE F**, Antonini G, Nardi F, De Berardinis E, Cristini C, Franco G, Sciarra A, Salciccia S. Mid-term outcomes of minimally invasive infrapubic approach for inflatable penile prosthesis implantation: A single-center study and literature review. *Andrology*. 2024;12(3):624–632.

IMPACT FACTOR (2023): 3,200

204. Ferro M, Chiujdea S, Vartolomei MD, Bove P, Porreca A, Busetto GM, **DEL GIUDICE F**, Antonelli A, Foschi N, Racioppi M, Autorino R, Chiancone F, Longo N, Barone B, Crocetto F, Musi G, Luzzago S, Piccinelli ML, Mistretta FA, de Cobelli O, Tataru OS, Hurle R, Liguori G, Borghesi M, Veccia A, Greco F, Schips L, Marchioni M, Lucarelli G, Dutto D, Colucci F, Russo GI, Giudice AL, Montanari E, Boeri L, Simone G, Rosazza M, Livoti S, Gontero P, Soria F. Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer*. 2024;22(2):27–37.

IMPACT FACTOR (2023): 2,300

205. Fuschi A, Pastore AL, Al Salhi Y, Martoccia A, De Nunzio C, Tema G, Rera OA, Carbone F, Asimakopoulos AD, Sequi MB, Valenzi FM, Suraci PP, Scalzo S, DEL GIUDICE F, Nardecchia S, Bozzini G, Corsini A, Sciarra A, Carbone A. The impact of radical prostatectomy on global climate: a prospective multicentre study comparing laparoscopic versus robotic surgery. *Prostate Cancer and Prostatic Diseases*. 2024;27(2):272–278.

IMPACT FACTOR (2023): 5,100

206. Glover F, Mehta A, Richardson M, Muncey W, DEL GIUDICE F, Belladelli F, Seranio N, Eisenberg ML. Investigating the prevalence of erectile dysfunction among men exposed to organophosphate insecticides. *Journal of Endocrinological Investigation*. 2024;47(2):389–399.

IMPACT FACTOR (2023): 5,100

207. Glover F, Sullivan E, Mulloy E, Belladelli F, DEL GIUDICE F, Eisenberg ML. The relationship between klotho, testosterone, and sexual health parameters among US adult men. *Journal of Endocrinological Investigation*. 2024;47(3):523–533.

IMPACT FACTOR (2023): 5,100

208. Ha AS, Scott M, Zhang CA, Li S, Langroudi AP, Glover F, Basran S, DEL GIUDICE F, Shaw GM, Eisenberg ML. Sociodemographic Trends and Perinatal Outcomes in Fathers 50 Years and Older. *JAMA Network Open*. 2024;7(8):e2425269.

IMPACT FACTOR (2023): 10,500

209. Kozikowski M, Zagrodzka M, Zawadzki M, Zugaj P, Osiecki R, Rzymkowski F, Śledź M, Sosnowski R, Dobruch J, DEL GIUDICE F, Krajewski W. The role of VI-RADS scoring criteria for predicting oncological outcomes in bladder cancer. *World Journal of Urology* . 2024;42(1).

IMPACT FACTOR (2023): 2,800

210. Lasorsa F, Bignante G, Orsini A, Bologna E, Licari LC, Bertolo R, DEL GIUDICE F, Chung BI, Pandolfo SD, Marchioni M, Fiori C, Ditunno P, Lucarelli G, Autorino R. Partial nephrectomy in elderly patients: a systematic review and analysis of comparative outcomes. *European Journal of Surgical Oncology* . 2024;50(10).

IMPACT FACTOR (2023): 3,184

211. Łaszkiewicz J, Krajewski W, Nowak Ł, Chorbińska J, DEL GIUDICE F, Sójka A, Mazur M, Pisarski S, Tomczak W, Małkiewicz B, Szydełko T. Retrograde intrarenal surgery using the ILY robotic flexible ureteroscope: a single centre experience. *Central European Journal of Urology*. 2024;77(1):136–139.

IMPACT FACTOR (2023): 1,400

212. Massanova M, Barone B, Caputo VF, Napolitano L, Ponsiglione A, DEL GIUDICE F, Ferro M, Lucarelli G, Lasorsa F, Busetto GM, Robertson S, Trama F, Imbimbo C, Crocetto F. The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naïve patients, according to the localization of the lesion at the mpMRI: A single-center retrospective

observational study. Prostate. 2024;84(13):1234–1243.

IMPACT FACTOR (2023): 2,600

213. Mirto BF, Barone B, Balsamo R, Abate M, Caputo VF, Sciarra A, Calogero A, Romano L, Napolitano L, Sciorio C, Lucarelli G, Lasorsa F, Ferro M, Busetto GM, DEL GIUDICE F, Manfredi C, Tătaru S, Pradere B, Imbimbo C, Crocetto F. Early and late post-procedural complications in different orthotopic neobladder surgical approaches: A systematic review. Surgical Oncology. 2024;55.

IMPACT FACTOR (2023): 2,300

214. Mori K, Yanagisawa T, Fukuokaya W, Iwatani K, Matsukawa A, Katayama S, Pradere B, Laukhtina E, Rajwa P, Moschini M, Albisinni S, Krajewski W, Cimadamore A, DEL GIUDICE F, Teoh J, Urabe F, Kimura S, Murakami M, Tsuzuki S, Miki J, Miki K, Shariat SF, Kimura T. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis. International Journal of Urology. 2024;31(1):25–31.

IMPACT FACTOR (2023): 5,900

215. Nowak Ł, Janczak D, Łaszkiewicz J, Guziński M, DEL GIUDICE F, Tresh A, Chung BI, Chorbińska J, Tomczak W, Małkiewicz B, Szydełko T, Krajewski W. Clinical and Oncological Outcomes Following Percutaneous Cryoablation vs. Partial Nephrectomy for Clinical T1 Renal Tumours: Systematic Review and Meta-Analysis. Cancers . 2024;16(6).

IMPACT FACTOR (2023): 4,500

216. Pandolfo SD, Cilio S, Aveta A, Wu Z, Cerrato C, Napolitano L, Lasorsa F, Lucarelli G, Verze P, Siracusano S, Quattrone C, Ferro M, Bologna E, Campi R, DEL GIUDICE F, Bertolo R, Amparore D, Palumbo S, Manfredi C, Autorino R. Upper Tract Urothelial Cancer: Guideline of Guidelines. Cancers . 2024;16(6).

IMPACT FACTOR (2023): 4,500

217. Pichler R, Stäblein J, Mari A, Afferi L, D'Andrea D, Marcq G, DEL GIUDICE F, Soria F, Caño-Velasco J, Subiela JD, Gallioli A, Tully KH, Mori K, Herms A, Pradere B, Moschini M, Mertens LS, Thurnher M. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer. Journal of Clinical Medicine . 2024;13(7).

IMPACT FACTOR (2023): 3,000

218. Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D, Mistretta FA, Luzzago S, Buonerba C, Cantiello F, Mari A, Minervini A, Veccia A, Antonelli A, Musi G, Hurle R, Busetto GM, DEL GIUDICE F, Ferretti S, Perdonà S, Prete PD, Porreca A, Bove P, Crisan N, Russo GI, Damiano R, Amparore D, Porpiglia F, Autorino R, Piccinelli M, Brescia A, Tătaru SO, Crocetto F, Giudice AL, de Cobelli O, Schips L, Ferro M, Marchioni M. Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database. Urologic Oncology: Seminars and Original Investigations. 2024;42(3):69.e17-69.e25.

IMPACT FACTOR (2023): 2,400

219. Pyrgidis N, Moschini M, Tzelves L, Somani BK, Juliebø-Jones P, **DEL GIUDICE F**, Mertens LS, Pichler R, Volz Y, Ebner B, Eismann L, Semmler M, Pradere B, Soria F, Stief CG, Schulz GB. Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis: Results from the GeRmAn Nationwide Inpatient Data Study. *Journal of Clinical Medicine* . 2024;13(12).
IMPACT FACTOR (2023): 3,000
220. Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, **DEL GIUDICE F**, Sciarra A, Mariotti G, Gentilucci A. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review. *Asian Journal of Urology*. 2024;11(2):191–207.
IMPACT FACTOR (2023): 2,400
221. Salciccia S, Moriconi M, Asero V, Canale V, Eisenberg ML, Glover F, Belladelli F, Seranio N, Basran S, De Berardinis E, Di Pierro G, Ricciuti GP, Chung BI, Sciarra A, **DEL GIUDICE F**. Systematic review and meta-analysis of serum total testosterone and luteinizing hormone variations across hospitalized Covid-19 patients. *Scientific Reports* . 2024;14(1).
IMPACT FACTOR (2023): 3,800
222. Sciarra A, Santarelli V, Salciccia S, Moriconi M, Basile G, Santodirocco L, Carino D, Frisenda M, Di Pierro G, **DEL GIUDICE F**, Gentilucci A, Bevilacqua G. How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy. *Cancers* . 2024;16(4).
IMPACT FACTOR (2023): 4,500
223. Seranio N, Muncey W, Cox S, Belladelli F, **DEL GIUDICE F**, Glover F, Eisenberg ML. Size matters: characterizing penile augmentation content from the 100 most popular YouTube videos. *International Journal of Impotence Research*. 2024;36(5):493–497.
IMPACT FACTOR (2023): 2,800
224. Stangl-Kremser J, Olivera L, Giudici S, Pradere B, Mertens LS, Albisinni S, Laukhtina E, **DEL GIUDICE F**, Afferi L, Soria F, Sforza S, O’Kelly F, Lammers RJ, Silay MS, Minervini A, Masieri L, Akhavan A, T Hoen LA, Moschini M, Mari A. application of the eraS guidelines in pediatric urological surgery: a systematic review. *Minerva Urology and Nephrology*. 2024;76(3):271–277.
IMPACT FACTOR (2023): 4,900
225. Tresh AS, **DEL GIUDICE F**, Li S, Basran S, Belladelli F, De Berardinis E, Asero V, Ferro M, Tataru S, Maria Busetto G, Falagario U, Autorino R, Crocetto F, Barone B, Pradere B, Moschini M, Mari A, Krajewski W, Nowak, Małkiewicz B, Szydełko T, Crivellaro S, Rane A, Challacombe B, Nair R, Chung BI. The Impact of Venous Thromboembolism on Upper Tract Urothelial Carcinomas Undergoing Open or Minimally Invasive Radical Nephroureterectomy in the USA: Perioperative Outcomes and Health Care Costs from Insurance Claims Data. *European Urology Focus*. 2024;10(2):317–324.

IMPACT FACTOR (2023): 4,800

226. von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein MW, Lonati C, Crocetto F, Taylor J, Tully KH, Afferi L, Soria F, **DEL GIUDICE F**, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, Lotan Y, Spiess PE, Black PC, Kiss B, Pradere B, Shariat SF, Albisinni S, Sarkis J, Antonelli L, Flippot R, Gallioli A, Khanna A, Maier E, Marcq G, Mori K, Penel N, Velez M, Woldu S. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. *BJU International*. 2024;133(3):341–350.

IMPACT FACTOR (2023): 3,700

227. von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, **DEL GIUDICE F**, Marcq G, Velez M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B, Afferi L, Antonelli A, Antonelli L, Bacchiani M, Bianchi A, Flippot R, Longoni M, Maier E, Penel N, Sarkis J, Soria F, Woldu S. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. *BJU International*. 2024;134(1):119–127.

IMPACT FACTOR (2023): 3,700

Luogo e data: **Roma, 23/08/2024**
